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ABSTRACT 
REGULATION OF TIE2 EXTRACELLULAR COMPLEX FORMATION IN 
ANGIOGENESIS 
By Annamarie Carter Dalton 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2015 
Director: Dr. William A. Barton 
Associate Professor, Department of Biochemistry and Molecular Biology 
Pathological angiogenesis is an essential component of tumor growth, 
development, and metastasis for which few effective therapeutic options exist. Though 
many cancer therapies target the function of cell surface receptors, mechanisms 
regulating membrane receptor crosstalk remain unclear. Two important families of 
receptors in angiogenesis, the Ties and Integrins, respond to the extracellular 
environment via outside-in and, in the case of Integrins, also inside- out signaling.  
Recent reports showed that the endothelial specific tyrosine kinase receptor, Tie2, 
xii
	  
	  
	  	  
forms complexes with two of the endothelial Integrin heterodimers, α5β1 and αVβ3, 
providing a convenient mechanism for the integration of extracellular stimuli. Our data 
confirm the interaction between Integrins and Tie2 and additionally indicate an 
interaction with the orphan co-receptor Tie1.  To elucidate the biological role of these 
macromolecular complexes, biochemical and biophysical methods including co-
immunoprecipitation, FRET microscopy, and cellular based assays were used to follow 
receptor/Integrin association in response to the Tie2 ligands Angiopoietin-1 and -2 as 
well as the Integrin ligand fibronectin. Furthermore, structural analysis by small angle x-
ray scattering of Tie2-ligand complexes and specific Integrin and Tie complexes are 
being used to identify the basis for growth factor receptor and Integrin signal 
transduction.   
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Chapter 1 
 Introduction 
1.1 Blood Vessel Development 
The vasculature of multicellular organisms evolved to perfuse tissues with 
oxygen, deliver nutrients, and transport physiological signals.  Early in development, 
angioblasts or mesoderm layer differentiated endothelial precursor cells, acquire a 
highly migratory phenotype to form the de novo meshwork of arteries and veins known 
as the primary capillary plexus. The early progression of angioblast migration to form 
the primary plexus is defined as vasculogenesis, a process that predominantly takes 
place during early development and results in similarly sized endothelial conduits.  
Many extracellular growth factors are required to coordinate the migration of angioblasts 
for vascular formation, the principal growth factor being Vascular Endothelial Growth 
Factor (VEGF) and its requisite signaling partners. 1–3 Recent literature has identified 
circulating endothelial precursor cells in the adult blood stream, implicating 
vasculogenesis in the mature vasculature.  Yet, the influence of vasculogenesis in the 
adult is considered small, where the process of angiogenesis (refinement of preexisting 
vessels) is both essential during development and for maintenance of the vascular 
network throughout life 4. 
Differentiation of angioblasts into endothelial cells is complete when the migrating 
cells make contact and create cell-cell junctions using the endothelial specific protein 
Vascular Endothelial-cadherin (VE-cadherin).  Moreover, this time point delineates the 
transition between vasculogenesis and angiogenesis 3.  Angiogenesis creates new 
1
blood vessels and capillaries by branching and remodeling the preexisting vasculature 
and is essential for various facets of the adult life, including wound healing and the 
female menstrual cycle 5.  
Comparable to vasculogenesis, angiogenesis is primarily regulated by VEGF and 
its receptors VEGFR1 and VEGFR2; however, angiogenesis is complex and requires a 
number of additional factors to modulate alterations of the vasculature.  The 
extracellular ligand VEGF-A prompts vascular permeability, proliferation, and 
vasodilation of existing vessels.  Permeability within the vasculature induces release of 
plasma fibrinogen, which upon conversion to fibrin will act as a temporary matrix for the 
migrating vasculature.  Additionally, Angiopoietin-2 (Ang-2), a context-dependent ligand 
antagonist for the endothelial specific receptor tyrosine kinase Tie2, is secreted at this 
point to disrupt contacts between the endothelial cells and their surrounding support 
smooth muscle cells called pericytes.  Matrix metalloproteinases and other proteases 
degrade the extracellular matrix of the vascular basement membrane at sites of 
branching to allow tip cells to move towards a chemoattractant such as VEGF-A.  To 
classify tip cells, upregulation of Delta-4 in response to VEGF-A activates Notch in 
directly adjacent endothelial cells and results in suppressed translation of VEGFR-2.  
Consequently, the initial cell is marked as a tip cell and migrates towards the highest 
concentration of a VEGF-A gradient.  Once a stalk begins to form behind the migrating 
tip cell, secreted proteins Angiopoietin-1 (Ang-1) and Platelet Derived Growth Factor-B 
(PDGF-B) work in concert to recruit additional pericytes for support of the newly formed 
vascular stalk.  Subsequent lumen formation within the stalks is necessary to establish 
blood flow, a process that requires Integrin molecules and the small GTPases CDC42 
2
	  
	  
	  	  
  
Figure 1.1 Blood Vessel Development 
During vasculogenesis, mesoderm originating angioblasts migrate in response to 
VEGF to form the primitive capillary plexus seen early in embryonic development.  
When angioblasts make contact and form junctions within the plexus, they have 
differentiated into endothelial cells and angiogenesis begins.  Angiogenesis is the 
process of branching and refinement of the similarly sized vessels in the primary 
capillary plexus to create a mature vasculature based on blood flow.  Angiogenesis 
occurs in response to VEGF and other factors including the Angiopoietins during 
development and throughout adult life. 
3
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and Rac1.  The stalk will eventually reach the source of angiogenic stimuli, typically 
another vessel during development and will fuse to form vascular loops.  In addition to 
creating the initial arteries, veins, and capillary beds of the body, angiogenesis 
continues past development into adulthood 6.  Specifically, angiogenesis plays a 
significant role at sites of active vessel remodeling, such as wound repair, skeletal 
growth, embryonic implantation or endometrial remodeling during the female menstrual 
cycle, in addition to its important role in many pathological conditions 7. 
 In contrast, lymphatic vessels develop from the embryonic venous system and 
when mature remove interstitial fluid from tissues.  Additionally, these vessels play an 
important role in the immune system by screening the returning fluid for signs of disease 
before reintroducing it into the blood stream.  Lymphatic vessels are created and 
maintained in a similar manner to blood vessels, typically utilizing different family 
members of the same receptor families.  For example, VEGFR-2 is the primary receptor 
for the important VEGF-A proangiogenic factor in blood vessel development.  In 
lymphangiogenesis, VEGFR-3 is upregulated and responds to stimulation by the ligand 
VEGF-C.  The Angiopoietin/Tie axis has also been established as an important 
component for proper lymphatic function though distinctions between its roles in 
angiogenesis versus lymphangionensis have not been as well characterized 8.  
 
1.2 Pathological Angiogenesis 
 1.2.1  Mechanisms 
According to the Angiogenesis Foundation, disorders associated with vascular 
remodeling currently affect more than 1 billion people around the world.  Unbalanced 
5
	  
	  
	  	  
angiogenesis can both result in, and exacerbate a multitude of disease states.  
Insufficient angiogenesis contributes to the pathology of coronary artery disease, stroke 
and chronic wounds, while excess angiogenesis is a major contributor to cancer, 
diabetic retinopathy, age-related macular degeneration, rheumatoid arthritis, psoriasis, 
and more.  In diseases characterized by underperfused tissues such as chronic 
ischemia, the therapeutic goal is to increase angiogenesis in order to circumvent 
blockages or damaged vessels and to reestablish proper circulation and oxygenation of 
tissues.  Alternatively, pathological states characterized by an excess of angiogenesis 
require either regression of superfluous vessels or re-normalization of the vasculature 2. 
 As stated previously, angiogenesis plays a significant role in tumor development 
and is considered one of the hallmarks of cancer 9.  Preliminary cancer research 
demonstrated that tumors were vascularized; however, it was generally believed that 
this vessel proliferation was a result of inflammation within the tumor environment 10.  
Initial growth of tumors under 3mm in size is supported by diffusion of oxygen and 
nutrients from nearby vessels, and at this volume, tumors are difficult to detect.  Early 
studies were unaware that tumors originated in an avascularized state.  Research in the 
1970’s, primarily by Dr. Judah Folkman, demonstrated that tumors around 3mm in size 
undergo an angiogenic switch that occurred even in the absence of inflammation.  Inner 
cells of the avascular tumor begin to experience hypoxic conditions, stimulating hypoxia 
inducible factor (HIF) to induce expression of soluble pro-angiogenic proteins.  Dr. 
Folkman crudely purified the secreted molecule, which he termed tumor angiogenic 
factor and found it capable of stimulating vessel growth up to 5mm from the site of the 
emerging tumor 10,11.  Soluble tumor angiogenic factors, primarily VEGF-A and 
6
	  
	  
	  	  
  
Figure 1.2 Pathological Angiogenesis 
Pathological angiogenesis occurs when an avascular tumor undergoes the hypoxic 
switch, releasing pro-angiogenic growth factors such as VEGF and Angiopoietin-2.  
Once the tumor is vascularized, it has the capacity to infiltrate distant sites through 
metastasis.  When vessels are stimulated with Ang-2 in the absence of VEGF, 
endothelial cell contacts are disrupted both with other endothelial cells and with the 
support pericytes, causing vessel regression.  As can be seen in quiescent 
endothelial cells, agonist Ang-1 secreted from support smooth muscle cells 
clusters and activates the receptor tyrosine kinase Tie2 and maintains pro-survival 
signaling. In the resting endothelium, the context dependent antagonist Ang-2 is 
expressed and remains in vesicles similar to Weibel Palade bodies within the 
endothelial cells for quick release.  The release of Ang-2 is triggered in branching 
endothelial cells to prolong expansion of the growing vessel stalk.  Tip cell release 
of PDGF-B recruits Ang-1 expressing support cells to create contacts with the 
endothelium and stabilize the newly formed vessel. 
7
	  
	  
	  	  
       
8
Angiopoietin-2, are up-regulated within cancer cells and released to initiate branching of 
the proximate existing vasculature. In addition to affording the tumor with an oxygen and 
nutrient source, the generated blood supply provides a mechanism for micro-
metastases to reach distant sites of the body 9.  
Interestingly, the tumor vasculature is characterized by its abnormalities, 
predominantly due to consistent and prolonged pro-angiogenic stimulation 7.  Vessels 
within a tumor are highly disorganized, long and tortuous.  They are poorly associated 
with the support pericytes, if pericytes exist at all, resulting in a thin and leaky vessel 
wall.  All of these factors cause the tumor vasculature to be very ineffective at delivering 
blood as compared to their normal counterparts. Therefore, renormalization and 
regression of the tumor vasculature have been a therapeutic goal for several decades 12. 
Additionally, immune cells play an important role in the progression of cancer and 
tumor growth, partly due to their effects on angiogenesis.  Specifically, tumor associated 
macrophages (TAMs) migrate towards sites of growing tumors and participate in the 
angiogenic switch, releasing VEGF-A and other pro-angiogenic factors including matrix 
metalloprotease-9 (MMP-9).  Tie2 expressing macrophages (TEMs) are a subset of 
TAMs that, when depleted from growing cancers, significantly reduce the tumor 
vasculature and lead to tumor regression.  As can be inferred from the name, Tie2 
expressing macrophages are one of the few cell types outside of endothelial cells to 
generate Tie2 protein.  Expression of Tie2 in these cells is upregulated in the tumor 
microenvironment due to hypoxic conditions, binding to excess Ang-2 produced during 
the hypoxic switch.  Ang-2 binding to TEMs decreases the secretion levels of TNFα and 
subsequently protects surrounding cells from apoptosis 13.   Additionally, it has been 
9
	  
	  
	  	  
speculated that TEMs serve as a guidance platform for the growing vasculature within 
the tumor environment and provide support to the newly formed branches.  Because of 
their functional role in cancer vascularization, TEMs have been examined as a 
promising therapy for ischemic conditions, potentially serving as a proangiogenic factor 
to aid in neovascularization of damaged areas 14.   
1.2.2  Angiogenic Cancer Therapies 
Currently, two schools of thought exist within the field of angiogenic cancer 
therapies.  Originally, Judah Folkman proposed to starve the tumor by inhibiting 
vasculature infiltration or by causing regression of preexisting vessels.  This approach is 
the basis for several FDA approved therapies including; sorafenib, cilengitide, sunitinib, 
and the well-known bevacizumab, also called Avastin.  All of these drugs target 
secreted ligands or cell surface receptors important in the angiogenic process and are 
predicted to have major antagonistic effects on cancer development.  However, their 
effect on human cancers has not been as profound as predicted, due to either adaptive 
resistance or intrinsic non-responsiveness in patients.  Typically, the tumor vasculature 
regresses along with a brief period of tumor quiescence following drug exposure.  
Unfortunately, the tumors will subsequently accelerate in growth, accompanied by 
reestablishment of the vasculature.  Interestingly, cancer cells post treatment with an 
antiangiogenic therapeutic tend to up-regulate expression of several pro-angiogenic 
paracrine factors including Fibroblast growth factor-1 and -2, Ephrin A1 and A2, and 
Angiopoietin-1.  Specifically, Ang-1 release will protect endothelial cells by establishing 
and strengthening contacts with support smooth muscle cells.   Alternatively, some 
tumors depend on a primary underlying group of existing blood vessels that are tightly 
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coated with support cells and are intrinsically resistant to the anti-angiogenic 
therapeutics.  Both mechanisms rely heavily on the interaction of the endothelial cells 
with the surrounding pericytes. The Tie/Angiopoietin signaling family is primarily 
responsible for regulating the interaction between these two cell types.  Therefore, this 
family is an attractive drug target to use in combination with existing FDA approved 
therapies or as a second round of treatment after resistance has developed 6.   
The latest concept in angiogenic therapies proposes to normalize the aberrant 
tumor vasculature.   Several labs are working towards this end with the idea that a 
normalized vasculature will improve drug delivery and relieve hypoxia within the tumor 
microenvironment, a condition that is known to decrease the efficacy of radiotherapies 
and immune responses 15.  Furthermore, a normalized vasculature with the 
appropriately formed support cell structure and basement membrane layer would 
decrease vessel permeability and decrease the ability of tumor cells to enter the blood 
stream and metastasize.   From this perspective, the Tie/Angiopoietin family will also be 
a valuable target for angiogenic cancer therapies.  
 
1.3 Tie Family of RTKs  
 1.3.1 Discovery of the Tie Receptor Family 
In the early 1990’s, a new class of receptor tyrosine kinase genes was 
discovered on mouse chromosome 4 that were specifically expressed in the developing 
endothelium and named tie-1 and tie-2 for tunica interna endothelial gene 16.  Genetic 
disruption of the tie-1 gene in mice leads to a destabilized vasculature characterized by 
edema and hemorrhaging, eventually causing death at embryonic day 13.5 17,18.  These 
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mice demonstrated the importance of the Tie1 receptor tyrosine kinase for the structural 
integrity of the vasculature.  Tie2 deficient mice perish by E10.5 with an unrefined 
vessel network and display branching defects.  The Tie2 knock out mouse, along with a 
dominant negative form of Tie2 and a single allele mutation, established the importance 
of Tie2 in multiple facets of endothelial cell function including differentiation, proliferation 
and survival 19.  Both Tie gene products were proven to be essential for vessel 
maturation and remodeling, yet have distinct regulatory functions.   
1.3.2  RTK Function and General Mechanisms  
Tie1 and TEK, or Tie2, are highly homologous receptor tyrosine kinase proteins 
(RTKs).  This family of 58 human membrane proteins is responsible for the transduction 
of signals from the extracellular environment to the inside of the cell by activation of 
their intracellular tyrosine kinase domains.  RTKs are conserved through evolution from 
Caenorhabditis elegans to man and play important roles in a variety of signal 
transduction pathways including cell survival, migration, proliferation, and many others.  
Due to their ubiquitous involvement in cellular function, misregulation of these receptors 
can lead to a wide variety of disease.  As such, RTKs are one of the most popular drug 
targets pursued by pharmaceutical companies.  Structurally, RTKs are comprised of the 
ligand-binding region followed by a single pass transmembrane domain and a tyrosine 
kinase domain within the cell.  All RTKs are activated in trans by another kinase domain 
typically in homodimeric or homomultimeric complexes, though heteromeric complexes 
exist as well.  The intracellular kinase domain has several conserved regions that act as 
regulatory loops including the juxtamembrane loop, activation loop, nucleotide binding 
loop and C-terminal tail sequences.  These regions are used in a variety of ways to 
12
	  
	  
	  	  
control activation.  Similarly, the ligand-binding region has evolved to accommodate a 
wide variety of ligand structures and clustering mechanisms to control activation of their 
receptors 20,21.   
1.3.3 Tie2 Structure 
Tie2 is the primary receptor of the Tie family and when activated induces a 
quiescent phenotype of the endothelium.  The extracellular domain of Tie2 forms an 
interesting arrowhead shaped structure that is comprised of three Ig like fold domains 
and three EGF repeats.  Three fibronectin type III repeats follow the third Ig domain to 
complete the extracellular region of the protein.  The X-ray crystal structure of the ligand 
binding region and a schematic representing the order of domains can be seen in 
Figures 1.3 and 1.4, respectively. To form the arrowhead structure, the first Ig domain 
folds towards the membrane and makes contact with the third Ig domain through Van 
der Waals and hydrophobic interactions.  The total fold buries 3800Å2 of surface area 
between Ig1, Ig2, Ig3, EGF1, EGF2, and EGF3 22,23.  The crystal structure of the full 
extracellular domain including the fibronectin repeats has not been solved to date nor 
has the structure of the related receptor Tie1.  However, several structures of the Tie2 
extracellular domain in complex with its Angiopoietin ligands have been solved and will 
be discussed in detail below.  
Intracellularly, the overall fold of the Tie2 kinase domain resembles the canonical 
fold of tyrosine kinases.  Of the reported RTK kinase domain structures, it is most 
similar to FGFR1, though modes of regulation differ between the two.  The split kinase 
domain has an N-terminal portion that includes the binding pocket for ATP, where the 
C-terminal domain contains catalytic residues and binding contacts for the substrate.  
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Figure 1.3 Crystal Structures of Tie2 and Tie2 Ligand Complexes. 
(A) The crystal structure of the ligand binding region of Tie2 (1-4) contains the three 
Ig domains and three EGF repeats colored with reference to Figure 1.4.  (B) Tie2 (1-
452) in complex with the fibrinogen receptor binding domain of Ang-1.  This Tie2 
construct contains the region used in the apo structure of Tie2 in addition to the first 
fibronectin repeat.  (C) Tie2(1-4) in complex with the fibrinogen domain of Ang-2.  (D) 
Overlay of all three structures shown in panels A-C.  The Angiopoietins, which are 
highly homologous, show very little rmsd deviation when bound to the Tie2 
extracellular domain.  Interestingly, there is almost no change in the structure of Tie2 
upon binding with either the agonist Ang-1 or antagonist Ang-2, emphasizing that 
functional distinction between the two ligands does not occur simply based on their 
mode of interaction with the receptor.  Additionally, Tie2 is not activated by a 
conformational change induced by binding of the ligands.  Instead, activation is 
primarily achieved through clustering of the ligands in their multimerization domains.  
(E) Crystal structure of the split tyrosine kinase domain of Tie2. 
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The two domains are bridged by a loop called the Kinase Insert Domain (KID) that 
causes the two lobes to form a cleft where catalysis occurs 24.   
As previously mentioned, the main regulatory loops of RTKs include the 
activation loop, the nucleotide binding loop, the juxtamembrane region, and the C-
terminal tail.  The juxtamembrane sequence is not included in the structure of the Tie2 
kinase domain and its role in regulation of Tie2 activation is not currently known.  The 
activation loop, or A-loop, in many RTKs including FGFR1 maintains an inhibitory 
position until phosphorylated, allowing for substrate binding and activation to occur.  
However, in the Tie2 structure, the activation loop is unphosphorylated and in an active 
conformation, indicating that the A-loop does not play a significant role in Tie2 
regulation by the standard mechanism.  The single tyrosine residue within this loop, 
Y992, does not appear to be the initial residue required for activation according to 
mutational analysis.  Alternatively, the nucleotide-binding loop appears to adopt an 
inhibitory conformation in the inactive structure, an unusual feature compared to 
homologous kinase domains 24.  The primary sequence does not indicate an obvious 
explanation for the difference.  Though a structure of the kinase domain with ATP bound 
has not yet been solved, modeling of the binding event does indicate that ATP is 
prevented from entering the pocket by the nucleotide binding loop.  
Typically, the activation loop is responsible for blocking the substrate binding 
pocket, though as mentioned above, the Tie2 activation loop does not appear to 
maintain typical RTK regulatory functions.  Interestingly, the C-terminal tail in the Tie2 
kinase structure adopts an inhibitory conformation that blocks the substrate binding 
pocket. Therefore, a conformational change of the C-terminal tail must occur for the 
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protein to be fully activated 24.  An inhibitory role for the C-terminal tail was confirmed in 
cells expressing a C-terminal truncation mutant of Tie2, terminated immediately 
following residue Y1107.  Several, but not all, key tyrosine residues within the C-
terminal tail remained within the mutant protein construct.25 Mutant protein has 
increased kinase activity in vitro and increased signaling through known downstream 
effector proteins in transfected cells. The phosphorylated tyrosine residues serve as 
docking sites for other adaptor proteins to interact with Tie2 and promote downstream 
signaling events.   
1.3.4 Tie2 Function 
Tie2 regulates endothelial cells during angiogenesis through interactions with its 
secreted Angiopoietin ligands and co-receptors at the cell surface.  
Immunohistochemistry analysis demonstrated that Tie2 is expressed throughout the 
vasculature, though it is upregulated at sites of angiogenesis in the adult mouse, for 
example at sites of wound repair and during folliculogenesis, and downregulated at sites 
of vascular regression. The broad expression pattern of Tie2 prompted studies of its 
activation state throughout the adult mouse.  Active and phosphorylated Tie2 was found 
to be present throughout the vasculature, indicating a role for Tie2 signaling in 
maintaining and supporting a quiescent vessel network 26.   
Activation of Tie2 is accomplished by homo-multimerization of the receptor 
through unique structural features of the Tie2 ligands.  Many studies have established 
that multimerization of Tie2 results in cross phosphorylation and activation of the split 
tyrosine kinase domain, in addition to phosphorylation of many residues in the C-
terminal tail 27. These phosphorylation sites bind bridge proteins with Src Homology 2 
17
Figure 1.4  Tie2 Receptor Regulation 
The Tie2 receptor tyrosine kinase consists of 3 Ig domains, three EGF repeats and 
three fibronectin type three repeats in the extracellular portion of the protein before a 
single pass transmembrane domain and split tyrosine kinase domain within the cell. 
4 known Angiopoietin ligands, Ang-1 through -4, bind to the head of the arrowhead 
shaped ligand binding domain at Ig2 with a one to one stoichiometry.  Ang-1 and 
Ang-4 are agonists of Tie2 and promote clustering of the receptor through 
multimerization of the Angiopoietin coiled coil and superclustering domains.  Tie2 
clusters cross-phosphorylate and activate pro-survival intracellular signaling through 
Akt.  Alternatively, the context dependent antagonists (Ang-2 and -3) function based 
on the presence of the highly homologous co-receptor Tie1.  When Tie1 is present, 
Ang-2 associates with Tie1/Tie2 complexes to prevent activation of Tie2.  If Tie1 is 
not expressed, Ang-2 is capable of clustering and activating Tie2 similar to Ang-1. 
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(SH2) or Phospho-Tyrosine Binding (PTB) domains and regulate signal cascade 
activation by bringing relevant effectors into close proximity 28.  Several of the known 
binding partners, including Grb2, Grb7, Grb14, Shp2, the p85 subunit of PI3K and DokR, 
were identified in the late 1990s by yeast two hybrid screening 27.  Grb2 and Shp2 
binding was localized to Y1101 and Y1112, respectively, both of which are known to 
signal through the Ras/MAPK pathway 29.  Conflicting experimental results have been 
reported about MAPK pathway activation in response to Tie2 stimulation.  Interestingly, 
in rat aortic ring plant experiments, MAPK inhibition decreased Ang-1 induced 
angiogenesis. However, this effect was not seen in isolated endothelial cells in culture 
30–32.  Therefore, factors that affect Tie2 mediated angiogenesis through MAPK are 
present in vivo but are missing in the ex vivo setting, likely because of either 
extracellular factors or alterations in expression of endothelial proteins. 
Alternatively, pro-survival signaling after cellular stimulation with the Tie2 agonist 
occurs predominantly through phosphatidylinositol 3 kinase (PI3K).  The C-terminal SH2 
domain of PI3K’s p85 domain was found to interact with several phosphorylation sites in 
the Tie2 C-terminal tail by yeast two-hybrid including pY1000, pY1106, and pY1037.  
The N-terminal SH2 domain of p85 was found to bind to pY1066 and weakly to pY1011 
27,33.  These interactions result in activation of the kinase and downstream signaling 
through Protein Kinase B, also known as Akt.  Akt signaling is required for endothelial 
cell survival and chemotaxis in response to the agonist Ang-1.  Through Akt activation, 
multiple pathways are initiated to prevent apoptosis and enhance cell viability including 
Survivin and eNOS, in addition to blocking pro-apoptotic factors such as Bad and 
transcription by FOXO1 30,34.  
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DokR was identified as a Tie2 signaling partner in endothelial cells through its 
PTB domain.  Once bound, DokR recruits Nck and subsequently p21 activated kinase 
(PAK), forming a complex at the cell membrane.  Once engaged in this complex, PAK 
kinase activity is increased and results in amplified motility of endothelial cells in 
response to activation of Tie2 35.   The intracellular signaling molecules discussed 
above are the predominant players in Tie2 signaling as we know them today.  However, 
it is likely that many other intracellular scaffold and signaling proteins are affected by 
Tie2 and Tie2/co-receptor complexes, which have not yet been discovered. 
1.3.5 Spatial Regulation of Tie2 
Several recent studies have examined the consequences of Tie2 localization on 
downstream signaling potential.  Specifically, in sparse cells lacking significant cell-cell 
contacts, Tie2 activation upregulates pro-proliferation and migratory signaling cascades 
in the presence of extracellular matrix.  Alternatively, in confluent cells, Tie2 is held at 
cell-cell contacts, likely through interactions in adherens junctions with VE-cadherin and 
VE-PTP.  At junctions, the agonist Angiopoietin-1 clusters Tie2 in trans, resulting in 
prosurvival signal activation and quiescence of the endothelium 36,37.  The specific 
mechanism, which results in the ability of Tie2 to activate distinct signaling pathways, is 
still largely unknown and will be explored in greater detail throughout this body of work.   
1.3.6 Tie1 
The secondary member of the Tie receptor family, Tie1, has been particularly 
difficult to characterize and remained controversial in the field for many years.  Tie1 is 
highly homologous to Tie2, maintaining 33% sequence identity across the entire protein 
and 76% homology within the split tyrosine kinase domain 16.  Interestingly, despite the 
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high level of conservation, 4 known Angiopoietin ligands regulate Tie2, yet Tie1 remains 
an orphan receptor.  Several studies have implicated Tie1 in weak binding events with 
the Angiopoietins though any phosphorylation event of endogenous Tie1 kinase domain 
required the presence of Tie2 38,39.  Previously, our lab identified Tie1 as a decoy 
receptor for Tie2, acting to disrupt Tie2 clustering and prevent activation of intracellular 
pro-survival signaling cascades 40.  Specifically, Tie1 interacts with Tie2 in a ligand 
independent manner through electrostatic interactions on the face of the ligand-binding 
domain of Tie2, though outside of the ligand binding region.  The agonist Angiopoietin-1 
disrupts the interaction between Tie1-Tie2, promoting Tie2 homomultimerization.  On 
the other hand, Angiopoietin-2 permits Tie1-Tie2 interactions presumably during active 
angiogenesis 40.  Further detail of the Angiopoietins’ role in Tie signaling is discussed 
below.   
Additionally, cleavage of the extracellular domain of Tie1 by matrix 
metalloproteinases further suggests its role as a decoy co-receptor antagonist.  
Proteinase activity results in release of a 45kDa soluble portion of Tie1 and increases 
phosphorylation of Tie2 in response to Ang-1, indicating a release of inhibition by 
removal of the co-receptor.  Functionally, intact Tie1 was found to downregulate Akt and 
42/44 MAPK phosphorylation, consistent with antagonizing Tie2 signaling 41.   
Finally, embryos lacking Tie1 have malformed capillaries with projections into the 
vessel lumen and increased capillary densities.  Additionally, the embryonic lethal 
phenotype due to edema and hemorrhage in Tie1 knockout mouse prompted the 
hypothesis that Tie1 plays a role in endothelial cell associations with the extracellular 
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matrix 18,42.  The observed phenotypes in Tie1 deficiency suggest that this orphan 
receptor tyrosine kinase may have multiple functions yet to be elucidated.   
1.3.7 Tie2 targeted therapeutics 
As discussed above, VEGF and VEGFR2 targeted therapeutics have not been 
as successful as anticipated.  Therefore, therapies directed towards distinct angiogenic 
pathways are being pursued for use in combination with current medications.  Recent 
reports state that high levels of circulating Ang-1 and low levels of Tie2 correlate with 
increased progression free survival in bevacizumab treated patients, clearly depicting a 
benefit in future modulation of the Angiopoietin/Tie axis in combination with VEGF 
pathway treatments 43.  Presently, there are no specific Tie2 targeting drugs approved 
by the FDA, though several pan-kinase inhibitors act to inhibit this RTK including 
Ponatinib and Regorafenib 44,45.  In clinical cancer trials, at least one small molecule oral 
agent, CEP-11981, has specific binding activity to VEGFR and Tie2 46.  In addition to 
CEP-11981, several clinical trials are currently being conducted against the Tie2 growth 
factor ligands, the Angiopoietins, discussed in the next section.   
1.4  Angiopoietin Ligands of Tie2 
1.4.1 Structure/Function of the Angiopoietin Ligands 
The four known Angiopoietin ligands, Ang-1-4, are responsible for regulating 
activation of Tie2.  These secreted growth factors possess significant structural 
homology, each consisting of a receptor binding domain at the C-terminus, followed by 
a coiled coil and N-terminal super-clustering domain 47.  The receptor-binding domain 
contains structural homology to a fibrinogen fold and is further subdivided into A, B and 
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P domains.  The P domain contains the receptor binding interface as well as a calcium 
chelating region.  Interestingly, the P domain maintains 73% amino acid conservation 
between Ang-1 and Ang-2 despite their ability to elicit opposite responses from the 
receptor upon binding 48,49.  The less characterized Ang-3 and Ang-4 are a murine 
homologue and human Tie2 agonist, respectively 50. 
Ang-1 is the primary ligand agonist for Tie2, which binds to its receptor in a one 
to one stoichiometry at the second Ig domain of Tie2 49.  As mentioned previously, the 
second Ig domain of Tie2 forms the tip of the arrow shaped extracellular domain, 
farthest from the membrane.  Binding of the ligand induces higher order clustering (for 
example, tetrameric, hexamer, and higher clusters) through the coiled coil and super 
clustering domains and induces transactivation of the split tyrosine kinase domain in the 
cytosol 47,51.  Ang-1 contains a free cysteine in the linker region between the fibrinogen 
domain and the coiled-coil that limits its solubility and preserves local concentrations.  
Pericyte smooth muscle support cells that line the resting endothelium express and 
secrete the ligand Ang-1.  The free cysteine sequesters it primarily in the extracellular 
matrix of the basement membrane sandwiched between the support cells and 
endothelial cells.  Unlike Ang-1, Ang-2 does not contain a free cysteine and is capable 
of migrating to distant sites to influence angiogenesis 52.   
Ang-1 knockout mice are embryonic lethal and are phenotypically similar to Tie2 
knockout mice.  These mice progress normally through vasculogenesis but perish by 
embryonic day 12.5, showing early growth defects in the heart at embryonic day 9.5.  
Compared to their wild type counterparts, Ang-1 deficient mice display a less intricate 
and poorly refined vasculature.  The vessels are dilated and lack the quantity of support 
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smooth muscle cells seen in wild type animals.  Furthermore, the extracellular matrix of 
the basement membrane is sparse and lacks proper fiber formation, revealing an 
altered microenvironment around the endothelium 51.   
Additionally, a Cre-Lox system was used to observe the effect of knocking out 
Angiopoietin-1 at later points in development in the whole animal or specifically in the 
heart or kidney.  Deletion of the floxed allele at E10.5 resulted in embryonic lethality and 
showed an increased number of vessels in the liver and lung that had a significantly 
higher vessel diameter and poor association with support cells.  Additionally, there was 
increased wound healing in ear punch cut outs of Ang-1 knockout mice initiated at 
E13.5 compared to control.  The authors noted that the vessels of the healed region 
appear to have normal association with pericytes, which is unexpected.  These findings 
generally fit with a pro-quiescent, pro-survival, anti-branching and anti-migratory 
mechanistic role for Ang-1 in murine knockouts 53.   
Conversely, dermal overexpression of Ang-1 in mice demonstrated the protective 
potential of this Tie2 ligand.  Dermal microvessel diameter is significantly increased in 
Ang-1 overexpressing mice compared to wild type and VEGF overexpressing mice.  
Despite increased vessel size, Ang-1 overexpression decreases plasma leakage.  
Alternatively, the VEGF overexpressing mice show increased vessel growth and 
increased vessel leakage.  When VEGF and Ang-1 were co-overexpressed in the skin, 
vessels were tortuous and had an increased diameter but were significantly less 
permeable than VEGF overexpression alone 54.  Plasma leakage is an important aspect 
of many pathological conditions influenced by angiogenesis including sepsis, diabetic 
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retinopathy and chronic inflammatory diseases. Therefore, Ang-1 could logically play a 
therapeutic role in the treatment of these significant pathologies.   
Unlike Ang-1, which stabilizes the quiescent endothelium, Ang-2 is involved in 
disruption of the vasculature during angiogenesis 55.  Ang-2 was originally cloned from 
cDNA libraries of mouse and human DNA based on its sequence homology to Ang-1.  
Ang-1 and -2 share 60% sequence identity and both bind to Tie2 with ~3nM affinity 55.  
Ang-2 also binds to the receptor with a 1:1 stoichiometry and is capable of forming 
higher order multimers through its coiled coil and super clustering domains, though 
studies have proposed that Ang2 primarily exists as a dimer physiologically 47,56.  Under 
typical conditions, Ang-2 competes for binding of the Tie2 receptor with Ang-1 and 
permits formation of Tie1/Tie2 inhibitory complex 40,55,57.  When in sufficiently high 
enough concentrations or in the absence of Tie1, Ang2 behaves as an agonist, 
clustering and activating Tie2 58.  Therefore, Ang-2 is a context dependent antagonist of 
the Tie2 receptor depending on the concentration of the ligand and the presence of the 
decoy co-receptor Tie1.   
When expressed in the presence of VEGF, Ang-2 promotes migration of vascular 
endothelial cells and expansion of growing stalks.  Alternatively, in the absence of 
VEGF, Ang-2 expression induces disruption of endothelial cell contacts and migration 
but results in regression of the vasculature.  Ang-2 is primarily expressed by endothelial 
cells themselves in response to endothelial cell stimulation by VEGF, IGF-1 and PDGFB 
for example 59.  Once translated, Ang-2 protein is held in intracellular compartments for 
quick excretion, and is released predominantly by tip cells to promote continued 
migration of the growing stalk. 
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Despite important regulatory functions in angiogenesis, the majority of Ang-2 
knockout mice are viable, though they perish within 14 days of birth in 129/J 
backgrounds with severe defects in the lymphatic system and postnatal vascular 
refinement.  Though Ang-2 does not appear to be essential for vascular development, it 
is required in adult life for proper repair and wound healing and is expressed only at 
sites of activated vessels undergoing angiogenesis 13,60.  Interestingly, overexpression 
of Ang-1 was capable of rescuing the Ang-2 defect in the lymphatic system but not in 
the vasculature 60.  This result suggests that Ang-1 and Ang-2 have similar roles in the 
lymphatic system yet distinct functions in vascular endothelial cells.  Interestingly, and 
consistent with its role as a Tie2 antagonist, Ang-2 overexpression in mice results in 
phenotypically similar problems within the vasculature as compared to both the Tie2 
and Ang-1 knockout mice 55. 
1.4.2  Angiopoietin roles in pathogenesis 
Misregulation of the Angiopoietin/Tie2 axis is involved in disease pathologies 
including cancer, sepsis, and many others.  Angiopoietin-2 is specifically upregulated in 
many cancer types during the hypoxic switch to help recruit vessels from surrounding 
tissues and correlates with stage progression and poor prognosis, making this molecule 
a useful biomarker 61.  It should also be noted that Ang-2 overexpression in the absence 
of VEGF-A leads to destabilization, random migration and apoptosis of endothelial cells, 
resulting in regression of the vasculature as opposed to branching; therefore, 
modulating Ang-2 could work in favor of anti-angiogenic therapies 62.    Several trials are 
working to target the Angiopoietin and VEGF pathways in concert to inhibit tumor 
angiogenesis and tumor growth 63,64.   
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Additionally, Ang-2 is upregulated in the blood stream and increases permeability 
of the endothelium during acute sepsis.  Furthermore, Ang-1, which promotes barrier 
function of the endothelium, is suppressed in Acute Respiratory Distress Syndrome 
(ARDS) indicating that the Tie2 axis is heavily modified in sepsis.  Proposed therapies 
for sepsis have had little translational success from the mouse to human.  Currently, 
Ang-2’s efficacy as a biomarker for sepsis is being pursued and its modulation is 
promising as a potential future therapeutic 65.   
 
1.5 Endothelial Integrins 
 1.5.1 Physiological Role of the Extracellular Matrix  
 It is clear from the immense literature that cell adhesion to extracellular matrix 
molecules is as critical as growth factor signaling for endothelial cell regulation.  The 
extracellular matrix (ECM) is composed of water, protein and polysaccharides existing 
either in the interstitial space or in tight matrices along epithelial or endothelial layers 
called basement membranes.  In vessel walls, the basement membrane exists between 
the luminal endothelial layer and surrounding support smooth muscle cells; each of 
these distinct cell types contribute to production of ECM proteins.  Components of the 
ECM are constantly changing, through both cellular excretion and a variety of post-
translational remodeling and modification processes, each of which controls a variety of 
physiological consequences 2,66,67.  The ECM not only acts as a support platform for 
neighboring cells but it also regulates cellular tension and acts as a ligand to initiate 
signaling cascades and a variety of other functions.  For example, during angiogenesis, 
the extracellular matrix provides mechanical signals and initiates signaling cascades 
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necessary for disconnected migrating endothelial cells to coordinate and organize into a 
functional endothelial conduit.  Multiple receptors, including Integrins, syndecans and 
discoidin domain receptors, exist on the cell surface to directly interpret the ECM and 
translate this information inside the cell 68,69.  Additionally, many growth factors, 
including Angiopoietin-1, interact with components of the extracellular matrix, limiting 
their range of diffusion and retaining them in a position to preferentially interact with 
surface receptors 52.  Coordinated signaling between growth factor receptor tyrosine 
kinases and extracellular matrix sensing molecules is a field of research currently under 
intense investigation due to the profound implications in human physiology and disease 
70. 
 1.5.2 Integrin Cell Adhesion Receptors 
The importance of Integrin receptor molecules cannot be overstated.  
Homologous sequences can be found back to prokaryotes and throughout the evolution 
of metazoa.  Their role in cellular adhesion and extracellular matrix recognition is 
essential for development of multicellular organisms, established by embryonic lethality 
resulting from the disruption of many Integrin molecules. Due to the shear volume of 
paralogs within humans, there appears to be a high level of compensation and 
redundancy, again highlighting the importance of proper function for survival. Finally, 
they are ubiquitously expressed; some Integrin pairs are highly tissue specific, while 
others maintain a widespread expression pattern 69,71.   
These heterodimeric type-1 single pass transmembrane proteins are comprised 
of one α and one β subunit, the combination of which confers ligand specificity 8.  There 
are 18 α and 8 β subunits, which combine to form 24 Integrin membrane receptors in 
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humans; 11 of these are expressed in endothelial cells.  Integrin receptors are uniquely 
capable of both outside in and inside out activation. On one hand, they take cues from 
the extracellular matrix and other soluble factors and transport that information inside 
the cell.  Alternatively, they may react to internal binding partners, thereby resulting in 
altered activation states outside of the cell.  The ability to undergo bi-directional 
signaling is a distinctive feature of this important membrane receptor class 72,73. 
1.5.3 Knockout Mice Targeting Endothelial Integrins 
In the endothelium, the primary fibronectin receptor, α5β1, and the less precise 
Integrin αVβ3 are specifically important for angiogenesis, though their individual 
functions have been difficult to determine due to compensation.  Interestingly, α5β1 has 
displayed consistently pro-angiogenic phenotypes while αVβ3 has been less consistent 
74.  Knock out of α5 in embryoid bodies demonstrated a defect in capillary plexus 
maturation resulting in large unrefined vessels; additionally, they demonstrated a slight 
decrease in secreted fibronectin 75.  The same studies examined αV knockouts and 
found no significant changes in the developing vasculature, which was surprising due to 
the previous determination that αV is upregulated in endothelial cells actively 
undergoing angiogenesis 76.  Similarly, the group of Dr. Richard Hynes completed a 
total mouse knockout of αV and found unanticipated development of the mice with ~20% 
surviving to term.  Unrestricted vasculogenesis and angiogenesis occurred in these 
mice, calling into question the importance of αV Integrins in vascular development 77.  
Furthermore, the α5-floxed endothelial specific mouse line showed very little angiogenic 
defect 78.   
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To clarify whether direct compensation was occurring between α5 and αV, a 
double knockout specific to endothelial cells was established, resulting in embryonic 
lethality during angiogenesis at E14.5.  Development of these embryos appeared 
normal through vasculogenesis until E11.5 when defects in the maturing vasculature 
became apparent, particularly in the great vessel and heart 78.  Therefore, it is clear that 
both α5 and αV are important in angiogenesis, yet they perform potentially redundant 
roles and are capable of compensating for one another.  
Similarly, knockouts of the Integrin β subunits are embryonic lethal prior to vessel 
formation, and therefore, their roles in vessel development have been analyzed through 
tissue specific knockouts.  Tie2-Cre and Tie1-Cre mediated excision of β1 results in 
lethality at the onset of angiogenesis, specifically E9-10.5 and E11.5, respectively 79,80.  
Endothelial specific β1 knockouts fail to properly refine the vasculature, impeding overall 
growth.  Interestingly, β1 knockouts are viable and fertile; however, they display signs of 
hemorrhaging and hypervascularized tumors.  Clearly, the four Integrin subunits 
discussed play significant roles in the development and maintenance of the mammalian 
vasculature. 
1.5.4 Integrin Function 
Integrin molecules perform multiple functions that make them critical for survival.  
Interestingly, Integrins respond in multiple ways to the extracellular milieu through 
formation of focal contacts and focal adhesions.  First, they initiate signaling cascades 
by organizing intracellular kinases at the plasma membrane.  Additionally, they establish 
a link for the actin cytoskeleton.  Intracellular processes extending from Integrins both in 
a cytoskeletal and signaling manner affect cell motility, proliferation, apoptosis, stability, 
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and cell shape based on the surrounding extracellular matrix.  As the cell migrates, 
Integrin containing complexes evolve from transient focal contacts (FX) that contain 
αVβ3 to more mature focal adhesions (FA) containing a mixture of α5β1 and αVβ3 and 
finally to fibrillar adhesions (FB), which solely contain α5β1 and remodel the ECM by 
promoting fibronectin fibril formation.  As the focal contact matures and the Integrin 
composition changes, alterations occur in intracellular scaffolding components and 
signal transducers to reflect the status of the cell 81.  
The overlapping and compensatory function of αV and α5 seen in the knockout 
mice is logical considering their dual existence in focal adhesions, though they have 
distinct functions in other Integrin adhesion complexes.  Extracellular variables including 
tension in the ECM and variations in the network of interacting partners provide the 
functional distinction between various types of adhesomes. Adhesomes are large 
complexes with many scaffolding proteins and signaling molecules recruited to the cell 
surface; however, at least some of these are distinctive between the various Integrin 
adhesion states.  For example, FXs contain talin and paxillin where FAs contain zyxin in 
addition to the FX components; finally, FBs contain tensin but FX specific components 
including paxillin are excluded 81.  Additionally, growth factor receptors are present 
within the Integrin adhesomes, creating another layer of temporal and spatial regulation 
that is currently under intense investigation and is not fully understood.   
Further comparison between the Integrins αVβ3 and α5β1 can be made in regard 
to their ligand specificity and intracellular trafficking patterns, which overlap yet have 
distinct differences.  α5β1 has been consistently observed as proangiogenic and binds 
primarily to fibronectin.  αVβ3 similarly recognizes fibronectin but recognizes a wide 
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Knockout Lethality Phenotype 
Tie1 E13.5 Fail to establish structural integrity of vessels; edema & hemorrhaging.  Defects in lymph angiogenesis. 
Tie2 E10.5 Defects in vascular network formation.  Lack of vessel branching. 
Angiopoietin-1 E12.5 Similar to Tie2KO.  Poorly refined & dilated vessels, heart defects, lack ECM development & pericytes. 
Angiopoietin-2 V Defects in wound healing. Overexpression of Ang2 is phenotypically similar to Tie2KO. 
αV (endothelial specific) 20% V Unrestricted vasculogenesis and angiogenesis. 
β3 V Some hemorrhaging and hypervascularization. 
α5 (embryoid bodies) 
(endothelial specific) 
E10.5 
V 
Large, unrefined vessels & decreased fibronectin. 
No blatant defects.  
β1 (total) 
(endothelial specific) 
E 
E10 
Not viable at pre-implantation stage. 
Severe vascular deficiencies. 
α5  and  αV E14.5 
Proceed normally through vasculogenesis until E11.5. 
Extensive defects in great vessel and heart. 
 
 
Table 1.1 Phenotypes of Relevant Knockout Mice 
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variety of additional extracellular proteins including vitronectin, Von Willebrand factor, 
thrombin and VEGFR2, all known for their pro migratory phenotypes.  Furthermore, αVβ3 
interacts with anti-angiogenic regulators including angiostatin and tumstatin 74.  
Controversy over αVβ3’s pro or anti-angiogenic effects has made it difficult to understand 
this Integrin’s role in blood vessel development.  
Finally, the Integrins αVβ3 and α5β1 are regulated by receptor recycling pathways 
to facilitate cell rolling and motility, which is also influenced by extracellular factors.  For 
example, both α5β1 and αVβ3 are recycled through the perinuclear recycling 
compartment in a Rab11 dependent manner in the absence of serum.  Interestingly, 
upon stimulation with PDGF, αVβ3 is transported through the early endosome and short 
Rab4 recycling pathway, in contrast to α5β1, which consistently undergoes transport 
through the PNRC Rab11 pathway 68,82,8381.  Collectively, Integrin internalization is 
dependent on the extracellular environment and is another layer of Integrin adhesion 
regulation.   
In relation to angiogenesis, αVβ3 is upregulated in activated endothelial cells, 
where α5β1 is prominent in endothelial cells at sites of newly recruited support smooth 
muscle cells.  The expression pattern of these Integrin subunits support a role for αVβ3 
to act as an initial sensor of the ECM in newly angiogenic migrating endothelial tip cells.  
The focal contacts developed in lamellopodia of migrating cells are transient and may 
either be dissolved or matured into focal adhesions containing both αVβ3 and α5β1, 
depending on the ECM sensed.  As the stalk becomes established, endothelial cells 
must create a functional lumen and recruit pericytes.  At this point, α5β1 migrates out of 
existing focal adhesions to develop fibrillar adhesions at the center of the cell 68.  
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Interestingly, α5β1 clustering by fibronectin increased force strength but αVβ3 responded 
to fibronectin clustering by inducing signal cascades and did not increase force strength 
84. Consistent with α5β1 anchoring phenotype, FBs promote remodeling of the ECM 
provided by the new pericytes and endothelial cells to develop a more mature basement 
membrane and support evolution into quiescent functional vessels 85.  
 The intracellular signaling networks initiated at the cell surface by the activated 
short cytoplasmic tail of Integrins are extensive.  Generally, Integrins are activated 
through an inside out mechanism that increases the affinity of the Integrin for its ligands 
through large conformational shifts that will be discussed below.  Once extended, the 
Integrin engages its extracellular ligands and initiates signaling within the cell by 
establishing contacts with a multitude of proteins at the intracellular leaf of the plasma 
membrane.  Subsequent clustering of the Integrin allows for stable focal adhesion 
assembly 86.  Eventually, the intracellular network will be disrupted and Integrins 
inactivated for a variety of physiological reasons. 
 Briefly, activation of Integrin molecules is typically achieved by binding of talin to 
the cytoplasmic tail of the β subunit with the help of the kindlin family of proteins 87,88.  
Once activated, paxillin and other scaffold proteins also bind to the cytoplasmic tails and 
recruit Integrin associated kinases such as Integrin linked kinase (ILK), focal adhesion 
kinase (FAK), and Src family kinases.  In addition to recruiting signaling molecules, 
activated Integrins link to the intracellular cytoskeleton specifically through the protein 
vinculin, which is known to bind talin, paxillin and F-actin.  The activated Integrin 
interacting network has been described as containing over 150 proteins with a wide 
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variety between the various Integrin subunits and therefore continues to be an important 
area of investigation 89,90. 
1.5.5 Integrin Structure 
As previously stated, Integrins are heterodimers of single-pass transmembrane 
proteins with large heavily glycosylated extracellular domains and short intracellular tails.  
The N-terminus of each Integrin mediates heterodimer formation between the α and β 
subunits and creates a head domain responsible for association with the extracellular 
matrix; ligand specificity varies based on the combination of subunits. Several high-
resolution crystal structures of the Integrins αVβ3 and α5β1 in conjunction with powerful 
biophysical assays have significantly advanced our understanding of the structure of 
Integrin molecules as it relates to their function. 
The first crystal structure of the full αVβ3 ectodomain at 3.1Å revealed the two 
subunits in a significantly bent conformation with 12 total domains, 4 in the α subunit 
and 8 in the β subunit.  Discrepancy within the α family of subunits exists near the 
ligand binding region as nine α subunits contain an insertion of an additional domain 
called the I-domain.  The two Integrins examined in this work, αVβ3 and α5β1, are 
members of the α subunit family that lack the I-domain as can be seen by structural 
studies and sequence analysis. The αV subunit head domain, responsible for both 
ligand interaction and heteromeric association with β3, consists of a seven bladed β-
propeller domain.  The stalk of the extracellular portion of the α subunit contains a thigh 
domain and 2 calf domains that adopt an Ig-like fold. The β subunit contains two Metal-
ion Dependent Adhesion Sites (MIDAS and ADMIDAS) in the N-terminal hybrid domain 
followed by a PSI domain, 4 EGF repeats and a β tail domain. The bent conformation 
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Figure 1.5  Integrin Regulation by Large Conformational Changes. 
Several complete crystal structures (PDB: 4G1E, 3VI4) were united to illustrate the 
large conformational shifts undergone during activation of Integrin molecules.  On the 
left, the bent inactive conformation of the α Integrin (grey) and β subunit (blue) is 
shown in the apo state.  The middle conformation depicts a potential intermediate 
step where the Integrin is extended but the head group remains in a closed state.  
The model on the right portrays an extended and active conformation in complex with 
the extracellular ligand RGD sequence of fibronectin (red) in a cleft at the membrane 
distal interface of the α and β interface.  
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observed in this structure was unexpected, as previous electron microscopy analysis 
had depicted the Integrins in extended confirmations.  This was some of the first 
evidence of large conformational shifts controlling Integrin function 91.   
Regulation of the Integrins is manipulated by significant changes in the 
extracellular domain forming either a drastically bent and inactive conformation in which 
approximately 2000Å2 of surface area is buried or an extended conformation.  The 
extended conformation exists in two states; either with a closed head similar to that in 
the inactive bent conformation or with an open head conformation that allows for ligand 
ligation.  Opening of the Integrin from the bent to the extended conformation upon 
activation is known as the switch blade model.  As discussed previously, it is generally 
accepted that activation is a result of Integrin associated proteins binding to the 
intracellular tails and forcing separation of the C-termini resulting in extension of the 
Integrin at the knees.   Elegant FRET experiments demonstrated that upon activation 
and extension of the extracellular domains, FRET between the α and β subunit tails of 
αLβ2 decreases 92.  Therefore, the intracellular domains of Integrin proteins move apart 
when activated.   
The crystal structures of both αVβ3 and α5β1 have been solved in complex with 
the interacting portion of the fibronectin protein.  The highest resolution crystal structure 
obtained with α5β1 at 2.9Å does not contain the full extracellular domain but instead 
includes the head and thigh domain of the α subunit and the β-A, hybrid and PSI 
domains of the β subunit.  The RGD peptide recognizes the Integrin in a cleft at the 
interface between the α and β subunits similarly to the ligand bound structure previously 
solved of αVβ3.  α5β1 demonstrates increased specificity for fibronectin through an 
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additional site of interaction adjacent to the RGD binding pocket.  The MIDAS within the 
β subunit requires a metal ion to be present, specifically a Mg2+ ion, to mediate ligation 
to ligands at the RGD binding site 93,94.   
1.5.6 Integrin Targeted Therapeutics 
Integrins α5β1 and αVβ3 are typically found at very low expression levels in 
epithelial cells; however, during tumorigenesis the expression of these Integrins is 
significantly upregulated.  As seen in Table 1.2 the Integrin αVβ3 is specifically 
upregulated in many cancers including melanoma, breast, prostate, pancreatic, ovarian, 
cervical and glioblastoma, while α5β1 is upregulated in melanoma and non-small-cell 
lung cancer.  Due to the importance of these molecules in the progression of cancer, 
several therapeutics have been created that target Integrin function.  Specifically, the 
well known Cilengitide is an antibody that blocks the Integrin αVβ3’s ability to engage 
with its ligands.  Unfortunately, this drug has not been as successful as anticipated in 
regressing tumors 95–97.  To this end, dual therapeutics that target both Integrin 
activation and its interacting partners could be interesting cancer therapeutics for the 
future.   
 
1.6 Receptor Cross-talk in Angiogenesis 
Another important aspect of Integrin function includes their ability to modulate 
the signaling potential of receptor tyrosine kinases including VEGFR2, PDGFRβ, HGF, 
and Tie2 to list a few that exist within adhesomes 98,99.  Crosstalk between these 
families of cell surface proteins creates another layer of temporal and spatial regulation 
that is currently under intense investigation.  For example, αVβ3 and VEGFR2 associate 
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Cancer Integrin expression Phenotype 
Melanoma α5β1 and αVβ3 
Vertical growth phase & lymph-node 
metastasis 
Breast αVβ3 and α6β4 Increased bone metastasis 
Prostate αVβ3 Increased bone metastasis 
Pancreatic αVβ3 Lymph node metastasis 
Ovarian αVβ3 and α4β1 Increased proliferation 
Cervical αVβ3 and αVβ6 Decreased survival 
Glioblastoma αVβ3 and αVβ5 Possible role in invasion 
Non-small-cell Lung 
Carcinoma α5β1 
Decreased survival in lymph-node negative 
tumor patients 
 
Table 2. Tumor Expression Pattern of αVβ3 / αVβ5 and Associated Phenotypes 95 
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in vivo and sensitize VEGFR2 to VEGF165 in the presence of vitronectin.  The complex 
is believed to form through initial activation of VEGFR2 by its ligand.  Activated 
VEGFR2 phosphorylates and activates the adaptor molecule c-src, which directs 
phosphorylation of the β3 cytoplasmic tail within αVβ3, promoting interaction between the 
two receptors in an inside-out signaling manner.  Physical association of αVβ3 and 
VEGFR2 is necessary for receptor sensitization and is likely necessary for full activation 
of VEGFR2 100,101.  
In contrast to VEGFR2, the role of Integrins in Tie2 signaling is significantly 
less clear.  Several studies have evaluated cooperative signaling between the Tie2 
growth factor receptor and Integrin molecules, implicating both αVβ3 and α5β1 as binding 
partners of Tie2 and its ligands, the Angiopoietins, though conflicting results have 
emerged.  Cascone et al. demonstrated a constitutive interaction between α5β1 (but not 
αVβ3) and Tie2, which was enhanced by fibronectin.  Interestingly, association with the 
Integrin receptor enriched Tie2 signalling in response to lower concentrations of Ang-1, 
demonstrating a significant physiological response to changes in macromolecular 
interactions 102.  Alternatively, Thomas et al. described a transient interaction between 
Tie2 and αVβ3 following stimulation with either Ang-1 or Ang-2.  After administering Ang-
2, they show recruitment of the downstream Integrin signalling partner FAK to the 
receptor complex followed by internalization and targeted degradation of the Integrin 103.  
The same group found Ang-2 to be capable of activating αVβ3 in endothelial cells 
independent of Tie2 104.  Direct binding of the Angiopoietin ligands to Integrin molecules 
has precedence in cell types that lack the endothelial specific Tie2 receptor such as 
neurons, cardiomyocytes and breast cancer cells, some sighting Ang-1 and others Ang-
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2 as the Integrin binding partner 105–107.  Contradicting reports can likely be attributed to 
compensatory roles of the Integrin molecules in angiogenic signaling, making it difficult 
to evaluate specific complex components and influences on Integrin-Tie interactions.  
In this work, we use multiple techniques to examine Tie2 engagement with a 
multimeric Angiopoietin ligand and characterize cross-talk between the Tie receptors 
and endothelial Integrins.  We demonstrate that both Tie receptors are capable of 
interacting with the essential angiogenic Integrins, αVβ3 and α5β1.  This interaction takes 
place through the arrowhead shaped ligand-binding domain of the Tie receptors in the 
absence of other cofactors.  However, the α5β1 ligand fibronectin does appear to 
stabilize the interaction with Tie2, implicating the extended conformation of the Integrin 
molecules in Tie2 binding.   We also demonstrate that Ang-1, but not Ang-2, is capable 
of interacting with the Integrins both in the presence and absence of its primary receptor, 
Tie2. Cooperation between the Tie receptors and αVβ3/α5β1 will be an attractive 
candidate in the development of future dual chemotherapeutics as both the Integrins 
and the Tie2 receptor are currently individual targets for the prevention of tumour 
angiogenesis and metastasis. 
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Chapter 2 
Structural analysis of a Tie2 multimeric complex 
Several previous structural studies analyzed the extracellular domain of the Tie2 
receptor and its mechanism of engagement with the Angiopoietin ligands 23,49.  High-
resolution data gained from these crystallographic inquires (Figure 1.3) illuminates 
significant features of Tie2 and the effects of ligand recognition, specifically 
underscoring the importance of multimerization in receptor activation.  The structure of a 
truncated form of Tie2 termed Tie2 (1-4), which includes the N-terminal Ig and EGF 
domains, revealed the formation of an arrowhead shaped structure with the 2nd Ig 
domain at the point within the ligand binding domain (Figure 1.3A).  As shown in 
subsequent complex structures, Ig2 provides the sole contact interface involved in 
ligand recognition with Ang-1 and Ang-2 (Figure 1.3 B&C).  Interestingly, upon ligation 
with either Ang-1 or Ang-2, there is no significant conformational change in either the 
ligand or the receptor (Figure 1.3D).  Co-crystals of Ang-1/-2 with Tie2 utilized the 
truncated monomeric C-terminal receptor binding fibrinogen domain of the 
Angiopoietins.  Native Angiopoietin protein contains two additional regions N-terminal to 
the receptor binding domain, namely the coiled-coil domain and a small super-clustering 
domain 47.  The coiled coil region presumably dimerizes the ligands while the super-
clustering domain mediates higher order multimerization including tetramers, hexamers 
and potentially larger homomeric complexes.  The 1:1 monomeric complex structures 
solved using the Angiopoietin fibrinogen domain demonstrated that a conformational 
change was not involved in receptor activation.  Instead, the coiled coil and 
superclustering domains are required to bring multiple Tie2 receptors into close 
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proximity, allowing for cross phosphorylation and activation of downstream signaling 
pathways.  Our goal was to structurally analyze a multimeric complex of Tie2 in order to 
better understand the mechanism involved in receptor activation. 
 
2.1 Structural Characterization of an Ang-2 Multimer 
2.1.1 Expression and crystallographic studies with Ang2-3A9 
Structural analysis requires highly pure and homogenous solutions of protein at 
high concentrations. Full-length Angiopoietin ligands naturally exist in a heterogenous 
mixture of multimeric states as described above.  A myc tagged full length version of 
Ang2 was purified and analyzed by TEM to determine whether various multimeric states 
could be distinguished from one another by this method.  However, we were unable to 
differentiate complexes by eye due to the resolution limit and size of our proteins.  
Therefore, in order to analyze the structure of a multimeric complex, it was necessary to 
create a truncated form of the ligand that would result in stable and homogenous 
multimers.   
Previously, the lab determined that N-terminal truncation of Ang-2 at residue 174 
results in a purified protein of 37 kDa that readily forms a homogenous multimer as 
assessed by size exclusion chromatography.  This protein, termed Ang2-3A9, includes 
the C-terminal fibrinogen like domain and 100 amino acids of the coiled coil region. 
Ang2-3A9 protein was subjected to large scale expression in mammalian cells and 
purified using a C-terminal human immunoglobulin Fc fragment fused to the protein of 
interest in a pcDNA3.1(+) hygromycin vector.  Mammalian cells are routinely used for 
protein purification in our lab; a flow chart for the procedure is shown in Figure 2.1 and 
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Figure 2.1 Schematic of Secreted Protein Purification from Mammalian Cells.127 
To make stable cell lines, typically pcDNA3.1 vectors containing the protein of 
interest fused to an immunoglobulin Fc tag are transfected into adherent HEK293 
cells and after a brief recovery period are placed under the appropriate antibiotic 
selection.  Cells expressing the plasmid form resistant colonies from single cells.  
These colonies are transferred to individual wells, expanded, checked for expression 
of the protein by SDS-PAGE and frozen for future use.  For large scale protein 
production, stable cells are seeded in rollerbottles at 37°C with 200 - 250mLs Hepes 
buffered DMEM with sodium bicarbonate, fetal bovine serum and penicillin / 
streptomycin.  The FBS concentration is decreased over the multiple week long 
expression period with media changes every 1-3 days depending on the confluency 
of the cells.  Harvested media is filtered to remove cellular debris and stored at 4°C 
with PMSF and Sodium Azide until purification proceeds.  For Fc tagged proteins, 
media containing the secreted protein of interest is loaded over a ProteinA column 
with appropriate volume for the anticipated protein load.  Once the media has flowed 
through, the ProteinA column is washed with Hepes buffered saline (HBS) and eluted 
using a 100mM Glycine buffer pH3 with 150mM NaCl.  Protein is eluted into fractions 
containing 1M Tris pH 8.8 at 1:10 the fraction volume to immediately neutralize the 
solution.  Fractions are analyzed by SDS-PAGE, pooled, concentrated, and 
introduced to a size exclusion chromatography column.  Fractions containing the 
purified protein are pooled and stored at -80°C, typically in HBS with 10% glycerol.  
To remove the Fc tag from purified proteins, either TEV protease or Thrombin, 
depending on the construct, are incubated overnight at room temperature with the 
protein of interest and separated using ProteinA sepharose.  A final size exclusion 
step is typically employed to ensure purity of the final product which is once again 
stored at -80°C in HBS with 10% glycerol. 
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described in the Materials and Methods section.  After thrombin cleavage and removal 
of the Fc tag, Ang2-3A9 protein analysis by gel filtration on an SD200 GL 10/300 
column indicated formation of a discrete multimer, eluting at 13.3 mLs (an approximate 
molecular weight between 75 and 150kDa).  
Pure Ang2-3A9 protein concentrated to 10 mg/mL was screened by hanging drop 
using the sparse matrix screens Wizard 1 & 2.  Crystals grew out of several conditions 
including 20% (w/v) PEG-3000, 100mM Tris pH 7.0, and 200mM Calcium Acetate; 20% 
(w/v) PEG-8000, 100mM MES, and 200mM Calcium Acetate; and 20% (w/v) PEG-8000, 
100mM Tris pH 8.5, and 200mM Magnesium Chloride.  The structure was determined 
by molecular replacement using the Ang-2 fibrinogen domain structure (PDB: 1Z3S) 
with a resolution down to 1.93Å.  Unfortunately, the electron density map showed no 
extra density available for the coiled-coil region.  Based on the crystal packing, there did 
not appear to be additional room available in the lattice for extra amino acids to exist 
(Figure 2.2).  Based on these findings, we presumed that the coil was cleaved and 
excluded from the growing crystal.  
In an attempt to gain further structural information about the full Ang2-3A9 protein, 
transmission electron microscopy (TEM) and small angle x-ray scattering (SAXS) 
techniques were both employed.  SAXS proved to be appropriate for the size and 
composition of our protein and showed potential for examining complex formation. 
Created in the 1930s to examine metal alloys, small angle x-ray scattering’s 
functionality has evolved to include the study of polymers, colloids, and biological 
macromolecules.  In structural biology, SAXS allows for determination of low-resolution 
shape analysis from protein or DNA/RNA in solution at relatively low concentrations 
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Figure 2.2 Purification and Crystallization of Ang2-3A9 
(A) Cartoon depiction of truncated Ang2-3A9 containing 99 amino acids of the coiled 
coil portion of the protein and fibrinogen domain.  (B) Ang2-3A9 protein was purified 
from HEK293 mammalian cells in rollerbottle culture as described in Figure 2.1.  Fc-
tagged and cleaved and separated proteins are shown from various stages of the 
purification process.  Tag free purified Ang2-3A9 is shown in lane 3.  (C) Ang2-3A9 
was crystallized out of several conditions including 20% (w/v) PEG-3000, 100mM Tris 
pH 7.0, and 200mM Calcium Acetate; 20% (w/v) PEG-8000, 100mM MES, and 
200mM Calcium Acetate; and 20% (w/v) PEG-8000, 100mM Tris pH 8.5, and 200mM 
Magnesium Chloride.  Oscillation data was collected at the Advanced Photon Source 
at Argonne National Laboratories.  (D/E) The crystal structure was refined to 1.93A.  
However, there was no additional density for the included coil. 
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compared to crystallography.  Analogous to X-ray crystallography, protein is exposed to 
a focused X-ray beam that creates secondary waves from the electrons present in the 
macromolecule and allows for detection of the intensities of secondary waves.  Unlike 
X-ray crystallography, the protein in solution is not uniformly ordered and therefore 
detailed information as to the high-resolution structure is lost. Nonetheless, SAXS 
analysis provides information about the overall size and shape of the protein, in addition 
to low resolution shape reconstructions from interatomic distance data.  
2.1.2 SAXS Evaluation of Ang2-3A9 Protein Solutions 
Three concentrations of purified Ang2-3A9 protein were sent to Lawrence 
Berkley National Labs for X-ray scattering analysis. The concentrations increased from 
1mg/mL to 3mg/mL, with the highest at 8.2mg/mL.  Radius of gyration (Rg) and Dmax 
determination for Ang2-3A9 protein showed that with increasing concentration, the size 
of the complex in solution increased dramatically.  Specifically, the Rg values were 
found to be 55.8, 67.8 and 87.0 for the low, medium and high concentrations, 
respectively.  The Rg of the Guinier region, or the low q data, provides a representation 
of the overall size and shape of the protein.   q is a measure the distance of the intensity 
data on the detector from the center of the beam.  Changes in the Guinier region can be 
seen in Figure 2.3C in the overlay of the scattering curves, intensity of q ( I(q) ) vs q 
(enlarged image of the region is seen in Figure 2.3D). The concentration dependent 
increase is not likely due to aggregation as the data at low q curves towards the axis 
instead of curving upward and increasing exponentially.   
From the Kratky plot ( I(q)*q2 vs q ) in Figure 2.3E, we gain information on the 
globular nature and dynamics of our protein. A globular protein with little flexibility 
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Figure 2.3 Ang2-3A9 Evaluation by Small Angle X-ray Scattering 
(A) Scattering profiles ( I(q) vs q ) obtained from varying concentrations of Ang2-3A9 
in solution obtained at Lawrence Berkley National Labs SIBYLS Beamline.  Protein 
was eluted at 8.2mg/mL (red) from an SD200 column in 2% glycerol Hepes buffered 
saline at pH7.4.  Decreased concentration samples at 1mg/mL (green) and 3mg/mL 
(blue) were diluted from the high concentration sample with column buffer taken pre-
void.  (B) Table of standard SAXS analysis values for each concentration. (C) 
Normalized scattering curves of the three profiles shown in A.  (D) Enlarged low q 
region exposing the size difference between the samples. (E) Kratky plots ( I (q) * q2 
vs q ) of 1,3 and 8.2mg/mL samples characterizing Ang2-3A9 as a multidomain 
protein with flexible linker regions.  (F)  P(r) functions used for Dmax determination 
(the largest distance between points of the protein in solution) again highlighting the 
difference in size with increasing concentration. 
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results in a curve with a Gaussian shape.  If the Kratky plot does not completely return 
to the axis, there is flexibility in the protein.  If the plot does not peak at all and continues 
in an upward trajectory, it is an unfolded protein.  The Kratky plots for all three 
concentrations of Ang2-3A9 assume an almost identical shape and depicts our protein 
to have multiple domains with a flexible linker.  The shape of the Kratky plot likely 
reflects the coil and fibrinogen domains separated by a short amino acid sequence 
without predicted secondary structure. 
The P(r) distribution function or pair wise function is another important 
representation of SAXS data achieved by performing a fourier transform on the 
scattering profile to create a representation of the interatomic distances within the 
protein.  Therefore, the point at which the P(r) function smoothly reaches the x-axis, 
Dmax, is the maximum distance between atoms in the protein.  A smooth Gaussian 
curve denotes a globular protein with spherical shape; any variation from a smooth 
curve can provide details about the existence of multiple domains and distinct 
architecture of the protein.  The P(r) functions of the three concentration data sets of 
Ang2-3A9 exemplify the change in overall size of the protein in different solutions 
(Figure 2.3F).  Interestingly, they all appear to have similar domain structures even 
though the Dmax significantly increases with increasing concentration. 
2.1.3 Prediction of the coiled-coil domain and modeling Ang2-3A9 
Upon detection of a concentration dependent protein size increase, we began to 
theorize as to the structural basis for this observation.  Previously, we believed Ang2-
3A9 to be a discrete dimer in solution based on the distinct nature of its elution profile by 
gel filtration and the substantial increase in size from the predicted elution of a monomer.  
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Therefore, we were surprised to discover that it appeared to be capable of changing 
oligomeric forms in solution.  The increase in shape could either be due to changes in 
the multimerization state of the coiled-coil domain or through homomultimerizing 
interactions within the fibrinogen domain of the protein. Coiled-coil domains have 
undergone extensive characterization and there are many programs available to predict 
both their existence and composition based on the protein sequence.  To begin, Coils, 
analyzed Ang-1 and Ang-2 a program through the ExPASy Bioinformatics Resource 
Portal, that determines the probability of a residue within the amino acid sequence of a 
protein to participate in parallel coiled-coil formation.  Ang-1 and Ang-2 are 498 and 496 
amino acids, respectively.  The coiled coil region of the full length Angiopoietin-1 protein 
was predicted to encompass residues 77 through 267.  Ang-2 was similarly predicted to 
have a coiled coil domain between residues 71 and 264 with the highest probability 
between approximately 150-250 (Figure 2.4A and B).  As previously stated, Ang2-3A9 
is N-terminally truncated to residue 174 and contains the region of highest coiled coil 
probability as depicted in Figure 2.4C. 
Subsequently, Builder was used to generate anticipated coil structures for full 
length Ang-1, full length Ang-2 and Ang2-3A9.  Briefly, predicted coiled coil sequences 
from the program Coils were input into Builder from which PDB files were generated for 
multiverse ranging from dimers to tetramers (Figure 2.5).  Builder uses the Rosetta 
score and BUDE score (Bristol University Docking Engine) to evaluate coil structures 
based on predicted free energy from anticipated bonding forces.  Interestingly, there 
were discrepancies between the coil predictions for Ang-1 and Ang-2.  Red boxes 
illuminate the most probable coils for each protein.  Specifically, scores suggest Ang-1 
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Figure 2.4 Coils Prediction of Full Length Angiopoietin Ligands and Ang2-3A9  
Coils ouputs from the ExPaSy bioinformatics Resource Portal for Full length Ang-1 
(A), Full length Ang-2 (B) and Ang2-3A9 (C) showing the parallel coiled coil prediction 
percentage versus residue. 
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forms a more stable dimer and pentamer while Ang-2 surprisingly had a significantly 
lower predicted free energy as a trimer.  The truncated sequence of Ang2-3A9 was also 
evaluated and the PDBs of parallel dimeric (green), trimeric (purple), tetrameric (blue) 
and pentameric (red) coils were built and displayed in Figure 2.5B.  The full Ang2 
trimeric coil is depicted in yellow for comparison.   
The Ang2-3A9 coils generated from Builder were used as input files for the 
ATSAS suite program Ensemble Optimization Method (EOM).  EOM employed the coils 
with appropriate symmetry, the known Ang-2 fibrinogen domain structure and the 
complete Ang2-3A9 sequence to generate 10,000 models for each multimer.  The 
models were subsequently clustered into ensembles and fit to the experimental SAXS 
intensity curves at both the low and medium concentrations (it was clear from initial test 
fits that the large size of the protein at high concentrations would not be satisfied using 
only these coils).  Model PDBs with chi-squared values close to one were generated as 
output files.  All PDB files generated from EOM for Ang2-3A9 were overlaid and shown 
in Figure 2.6A.  The 6 best models were isolated based on their fit using FOXS and P(r) 
function comparison, which will be more thoroughly discussed below.  These six models 
are shown both as an overlay in 2.6B and tiled in 2.6C.   
2.1.4 Model Comparison to Ang2-3A9 Experimental Data 
P(r) functions and theoretical intensity curves for output PDBs were compared to 
the experimental data using primarily Scatter and the FOXS webserver.  Interestingly, 
various models from both the trimeric and tetrameric pools fit to the lowest 
concentration Ang2-3A9 data.  All generated PDBs were too small to fit the medium or 
high concentration data as seen in the Guinier region of the data.  FOXS generates a 
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Figure 2.5 CCBuilder scores and generated PDBs for Full Length Ang1, Ang2 
and Ang2-3A9 
(A) Output data from CCBuilder v1.0 showing the Rosetta and BUDE predicted free 
energies of each protein ensemble.128  (B) Generated PDB outputs for the Ang2-3A9 
dimer (green), trimer (purple), tetramer (blue) and the full length trimeric coil of Ang2 
(yellow). 
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Figure 2.6 EOM created models of Ang2-3A9 as a dimer, trimer and tetramer. 
The ATSAS suite program EOM generated 90,000 total models of Ang2-3A9, 10,000 
as a dimer, 10,000 as a trimer and 10,000 as a tetramer for each of the concentration 
data sets.  Only the models that best fit the experimental data were output as PDB 
files.  All generated PDBs are shown in (A).  (B/C) Generated PDB files were 
compared to experimental scattering profiles using the FOXS webserver and to the 
P(r) functions using Scatter.  The top six models are shown overlaid as well as tiled in 
B and C, respectively. 
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theoretical scattering profile from PDB files and runs statistical analyses to provide a 
measure of fit to the experimental data represented as chi.  Dmax values and FOXS 
calculated chi values for each of the 6 best models are presented in Figure 2.7A.  The 
04661 model (Figure 2.7B) fit well to both the P(r) function of the low concentration 
Ang2-3A9 data and the theoretical scattering curve, with a chi value of 0.51 (Figure 
2.7C).  The P(r) functions for the low (cyan), medium (purple) and high (blue) 
concentration experimental data are all shown in Figure 2.7D with the overlay of the 
04661 theoretical P(r) function in red.  Surprisingly, none of the models generated with 
the dimeric coil were large enough to fit the experimental data of the low concentration 
data.  Similarly and as stated previously, none of the generated trimeric or tetrameric 
forms of the protein had a Dmax large enough to fit either the medium or high 
concentration data.  Therefore, we looked to generating an ab initio envelope of the 
data to guide modeling of a larger conformer. 
The Monsa ab initio envelope of Ang2-3A9 (Figure 2.8A) visually appeared to 
dimerize two coiled models at high concentrations through interactions of the Ang2 
fibrinogen domains.  This theory was tested by merging two copies of the 04661 output 
model, the best fit to the low concentration Dmax and experimental curve, to create a 
dimer of trimers through the free fibrinogen domain (Figure 2.8B).  The dimer was 
compared to high concentration data by using FOXS and MultiFOXS webservers to 
evaluate the theoretical scattering profiles.  The 04661 dimer created fit well to the high 
concentration scattering profile (Figure 2.8C) and the Dmax, though slightly small, 
maintained a very similar profile (Figure 2.8D).  In solution, this dimer of multimers is 
likely flexible in a variety of directions through the short linker between the coil and the 
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Figure 2.7 EOM Model Comparison to 1mg/mL Ang2-3A9 SAXS Experimental 
Data 
(A) Dmax and FOXS chi values of the best 6 generated EOM models shown in Figure 
2.8C.  (B) 04661 fit both the P(r) function and the low concentration experimental 
data through FOXS better than any of the other models.  (C) FOXS fit of the 04661 
model to the low concentration data. (D) Predicted P(r) function of 04661 (red) 
compared to the low concentration data (cyan), medium (purple) and high (blue) 
concentration data.  
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Figure 2.8 EOM Model Comparison to the 3 and 8.2mg/mL Ang2-3A9 SAXS 
Experimental Data  
(A) Monsa ab initio envelope reconstruction of the medium concentration data. (B) 
Two 04661 models dimerized through the fibrinogen domains roughly based on the 
Monsa envelope. (C) FOXS fit of the 04661 dimer of trimers to the high concentration 
data with a chi of 2.86.  (D) Dmax overlay of the 04661 dimer of trimers (red) on the 
high concentration Ang2-3A9 experimental P(r) function (green). (E) FOXS fit of both 
the 04661 trimer (green) and the 04661 dimer of trimers (blue) to the 3mg/mL 
concentration data.  (F/G) The monomer fit with a chi of 1.4.  A 72.7% trimer mixed 
with 27.3% dimer of trimers fit the data with a chi of 0.92. 
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fibrinogen domains; any movement may account for the slight discrepancies in the P(r) 
function and FOXS analysis.  Interestingly, the dimer of trimers is too large for the 
medium concentration experimental data.  Therefore, we hypothesized that the medium 
concentration exists as a mixture of the trimer and dimer of trimers.  This hypothesis 
was supported by FOXS analysis with a minimum ensemble search.  The dimer 04661 
model fit to the medium concentration data with a Chi value of 1.4, but the complex was 
obviously too small in overall size as seen in the low q data range, despite fitting to the 
remaining curve quite well.  When FOXS analyzed the trimer and dimer of trimer models 
simultaneously, representing a mixture of the two in solution, it found that a mixture of 
77% trimer and 27.3% dimer of trimers fit to the medium concentration experimental 
curve with a chi value of 0.92 (Figure 2.8 E, F, G).  Therefore, we believe that Ang2-3A9 
exists as a trimer in solution at low concentrations, and with increasing protein in 
solution, the trimers are able to form higher multimers with a low affinity interaction 
through the fibrinogen domain. 
 
2.2 Examination of a Multimeric Ang-2/Tie2 Complex 
2.2.1 SAXS Analysis of the Tie2 ligand-binding domain  
Previously solved crystal structures demonstrated a one to one binding 
stoichiometry between Tie2 and its physiological ligand Ang-2 23.  The P domain within 
the fibrinogen like fold of Ang-2 directly interacts with Ig2 in the arrowhead shaped 
ligand-binding region of Tie2.  Interestingly, there was very little change in the overall 
structure of Tie2 when compared to the protein in complex with Ang-2.  Therefore, the 
Angiopoietins use an alternative mechanism to activate their receptor tyrosine kinase, 
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Figure 2.9 SDS-PAGE Analysis of Ang-2/Tie2 SAXS Complexes  
All individual proteins and complexes were run on a 10% SDS-PAGE gel to analyze 
purity and complex protein ratios.  Gel was stained with Coomassie Brilliant Blue. 
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explicitly by clustering through the coiled coil and super-clustering domains.   
To complex the receptor with our multimeric version of Ang-2, Ang2-3A9, we 
purified Tie2 (1-4), a truncated version of the extracellular portion of the protein used in 
previous structural experiments.  This protein contains three Ig domains and three EGF 
repeats that form the arrowhead shaped structure essential for recognition of the 
Angiopoietins.  It does not contain the three membrane proximal fibronectin repeats that 
connect the ligand-binding region to the transmembrane domain.  Several high-
resolution structures of this protein have been solved, both alone and with the fibrinogen 
domains of both Ang-1 and Ang-2 (Figure 1.3).  Therefore, we can easily compare our 
SAXS data with the known crystal structure to validate analytics.   
SAXS scattering profiles for three concentrations of Tie2 (1-4) alone (1, 3.3, and 
10 mg/mL) are shown in Figure 2.10A and overlaid in 2.10B.   There was no indication 
of concentration dependence in the scattering profiles, the Kratky plot (Figure 2.10C) or 
the P(r) plots (Figure 2.10D).  The protein appears to be tightly folded with only a small 
amount of flexibility as seen in the Kratky plots in Figure 2.10C.  The calculated Dmax 
from the P(r) plots was 112 for all concentrations.  To create an ab initio reconstruction 
from our medium concentration experimental data, 20 Dammif runs were completed 
before averaging and filtering with Damaver, all programs from the ATSAS suite.  As 
can be seen in Figure 2.10E, the high-resolution crystal structure fits well within the 
Dammif ab initio model.  Interestingly, despite fitting well within the envelope, the Tie2 
(1-4) crystal structure fit to the experimental data with a chi of 6.85.  Our collaborators, 
Michael Hammel and Caroline Weiss, used BILBOMD to model a small amount of 
flexibility between the third EGF repeat and the third Ig domain, where high B-factor 
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Figure 2.10 SAXS analysis of Tie2 (1-4) alone 
(A) Scattering profiles of Tie2 (1-4) protein at 1, 3.3, and 10 mg/mL in 2% glycerol, 
20mM Hepes pH 7.4, 150mM NaCl.  (B) After normalizing the intensities, it was clear 
that there were no concentration dependent changes in protein composition.  (C) The 
Kratky plots of all Tie2 (1-4) concentrations confirm a globular well folded protein.  (D) 
P(r) functions indicate a single domain and result in the same Dmax for each 
concentration.  (E) Dammif constructed ab initio envelop of Tie2 (1-4) fits well to the 
previously solved crystal structure (PDB:2GY5). (F) Table showing the standard 
SAXS analysis values for Tie2(1-4) protein alone in solution.  (G)  2GY5 structure 
with residues characterized by high B-factors shown in green.  BilboMD was run 
maintaining the EGFs and Ig1/2 as one domain and Ig3 as a second domain.  Two 
models (purple and yellow) fit the data better than the crystal structure. (H) FOXS fit 
of the crystal structure (blue) and BILBOMD model (green) demonstrating potential 
for slight flexibility in the linker region between EGF3 and Ig3, though a dramatic 
amount of flexibility is unlikely.   
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values existed in the x-ray crystal structure (2.10G).  These models were not as tightly 
packed as the original crystal structure but significantly improved the fit to the 
experimental data with a chi value of 1.81 (2.10H).  
2.2.2 Complex Formation of Ang2-3A9 with Tie2 (1-4) 
Ang2-3A9 was complexed with the ligand-binding domain of Tie2 and purified 
away from monomeric contaminants using gel filtration chromatography.  To ensure 
complete complexation of Ang2-3A9, excess Tie2 was mixed on ice before separation 
by a Superdex200 10/300 column.  There was a distinct shift in the elution profile of the 
complex compared to either Ang2-3A9 alone or Tie2 (1-4) alone (Figure 2.11).  It should 
be noted that though Tie2 (1-4) is a larger monomer than Ang2-3A9, Ang2-3A9 elutes 
as a multimer by size exclusion.  The leading edge of the complex elution was 
concentrated and utilized for structural analysis. 
Early in our analysis of the complex, we attempted to gain structural insight into 
our protein using Transmission Electron Microscopy.  Briefly, we negatively stained our 
protein incubated on carbon grids with uranyl formate (Figure 2.12).  Unfortunately, the 
size of our protein complex makes single particle analysis difficult and, therefore, we 
decided to proceed with small angle x-ray scattering to characterize our proteins in 
complex. 
2.2.3 SAXS Evaluation of the Ang2-3A9/ Tie2 (1-4) Complex 
Of the three concentrations of Ang2-3A9 / Tie2 (1-4) complex sent for SAXS data 
collection, it appeared that only two were suitable for analysis, the 2.5 and 5 mg/mL 
solutions.  The 1mg/mL concentration sample appeared to have buffer subtraction 
problems during data refinement and, therefore, is not shown in Figure 2.13.  
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Figure 2.11 Ang2-3A9 / Tie2(1-4) Complex formation by Size Exclusion 
Chromatography 
Tie2 (1-4) (red), Ang2-3A9 (green), and the Ang2-3A9/Tie2(1-4) complex (blue) were 
run on an SD200 10/300 column in 2% glycerol with 20mM Hepes pH 7.4 and 
150mM NaCl.  Chromatographs were subsequently overlaid to depict the shift in 
elution profile upon complex formation.  Additionally, the complex was formed with 
excess Tie2(1-4) to ensure complete complexation of Ang2-3A9 resulting in the 
elution of a second peak in the complex run of the surplus free Tie2(1-4). 
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Figure 2.12 Transmission Electron Microscopy of the Tie2 (1-4) / Ang2-3A9 
Complex. 
Carbon grids incubated with protein from each of the samples shown in Figure 2.11 
were negatively stained with Uranyl Formate and imaged by Transmission Electron 
Microscopy.  It became evident that our complex was undersized for TEM and we 
therefore focused on SAXS for further analysis of the complex. 
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Surprisingly, the two higher concentrations did not appear to demonstrate a 
concentration dependent overall protein size increase as seen in the scattering curve 
(Figure 2.13 A and B) and calculated Rg values from the Guinier region of the scattering 
curve.  The two solutions of the complex also have similar Kratky plots (Figure 2.13D), 
which show a globular fold with some flexibility.  Interestingly, when compared to Ang2-
3A9 alone, the initial shoulder of the Kratky plot is lost, which in the Ang2-3A9 alone 
data likely represents the distinct dimers of trimers as the shoulder becomes 
increasingly prominent with increased concentration.  Additionally, the P(r) functions of 
the complex at 2.5 and 5 mg/mL do not have dramatic changes in size with increasing 
concentration in contrast to Ang2-3A9 alone (Figure 2.13E).  Instead, either 
complexation with Tie2 prevents the higher order multimerization we saw when the 
ligand was alone at high concentrations or we do not have high enough concentrations 
to see this effect with the complex.  Consistently, the Dmax values calculated from the 
P(r) functions were fairly stable at 224 and 233 for the medium and high concentrations, 
respectively.  
Similar to our analysis with Ang2-3A9 alone, EOM models were calculated for the 
medium and high concentration data using the dimeric, trimeric and tetrameric coils 
from CCBuilder as fixed domains.  60,000 models were generated using these coils, the 
complex structure of the Ang2 fibrinogen domain with Tie2 (1-4) and the complete 
sequence as input files.  Of the 60,000 models created, only 39 PDB files were written, 
which represent the best fits to the experimental data.  These 39 models were clustered 
and presented in Figure 2.14A.  Each of the models were analyzed by FOXS for fit to 
the experimental data and their theoretical P(r) functions were visually assessed for 
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Figure 2.13 SAXS Analysis of Tie2(1-4) in complex with Ang2-3A9 
SAXS data for the low concentration of the Ang2-3A9 complex and Tie2 (1-4) could 
not be properly buffer subtracted.  Therefore, only the medium (blue) (2.5mg/mL) and 
high concentration (green) (5mg/mL) results are shown.  (A/B) Scattering profiles for 
Ang2-3A9/Tie2 (1-4) complex separated by intensity values (A) and normalized (B).  
The concentrations overlay well particularly in the low q range depicting no 
aggregation or multimerization differences at these concentrations (C) Table of 
standard SAXS analysis values for the varying concentrations. (D) Kratky plot of the 
complex at medium and high concentrations indicating a large globular structure with 
a small amount of flexibility.  (E) P(r) functions of the medium and high concentration 
data show that there is little difference in the shape of the protein at different 
concentrations and provide a Dmax of 224 and 233 for the medium and high 
concentration data, respectively. 
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Figure 2.14 All Generated PDBs from EOM for the Ang2-3A9 Complex and Top 
Six Fits 
90,000 EOM models were generated using the dimeric, trimer, and tetrameric Ang2-
3A9 coils and the Ang2 fibrinogen domain + Tie2(1-4) crystal structure as input 
domains.   (A) All output PDB files overlaid.  (B) The top 6 PDB files as determined 
by chi values in FOXS and shape fits to the experimental P(r) functions in Scatter. 
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adequate overlap with the P(r) functions calculated from the medium and high 
concentrations.  The best models based on these parameters were tiled and shown in 
Figure 2.14B.   
2.2.4 Comparison of the Ang-2-3A9 Complex with EOM Generated Models 
 Four dimeric models and two trimeric models comprised the top six fits to the 
experimental data for the Ang2-3A9 / Tie2 (1-4) complex.  Surprisingly, all of the top 6 
models show one Ang2 fibrinogen domain in complex with a Tie2 (1-4) molecule 
apparently contacting the coiled coil domain and pointing away from the other fibrinogen 
domain/ Tie2 molecules.  The best fit through both FOXS and P(r) function analysis was 
the dimeric 00229 model, which received a low chi value of 1.84 (Figure 2.15A/B).  
Despite having a good overall fit to the experimental data, the theoretical scattering 
curve for 00229 did not accurately represent the data in the low q / Guinier region.  
Therefore, the top two dimer models and top two trimer models were displayed 
simultaneously on the experimental scattering curve to attempt to accurately assess the 
overall size of the protein in solution (Figure 2.15C/D).  Figure 2.15D clearly 
demonstrates the size discrepancy between our generated models and the 
experimental protein despite a good fit to the remaining data.   
Therefore, we hypothesized that our protein existed in a trimeric coil state but 
was only partially complexed with the Tie2 (1-4) protein in solution.  To this end, we 
systematically deleted each of the Tie2 (1-4) molecules sequentially in all of the trimeric 
model PDB files.  Additionally, we deleted each Ang2 fibrinogen domain and Tie2 
molecule position within each trimeric model in case we had again experienced 
proteolytic cleavage of a fraction of the Ang2-3A9 protein in solution.  Based on analysis 
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Figure 2.15 FOXS and P(r) fitting of EOM models to the Ang2-3A9 / Tie2 (1-4) 
Complex experimental data. 
(A) All EOM generated models were fit to the medium and high concentration SAXS 
data of the Ang2-3A9 / Tie2 (1-4) complex.  The best fit was model number 00229, 
which was created using the dimeric coil fit to the high concentration data.  As show 
in A, the theoretical scattering profile of 00229 fits well to the high concentration data 
with a Chi value of 1.84 though there are fairly significant discrepancies in the P(r) 
function overlay (B).  The largest residuals observed in FOXS analysis were in the 
low q region of the data suggesting that the dimeric model of the complex is slightly 
too small to represent what is in solution.  (C) The top two dimeric models (red and 
green) were compared to the top trimeric models (cyan and yellow) to see if the 
trimeric models displayed a better fit to the low-resolution data.  Unfortunately, the 
dimeric models appeared to be too small while the trimeric models were slightly too 
large as can be better visualized in the enlarged panel shown in D.  Tie2 subunits 
and Ang2 fibrinogen domains/ Tie2 subunits were systematically removed from each 
of the generated trimeric models to create partial trimer models.  The FOXS plot 
shown in panel E represents the best partial trimer generated from model 04305.  
This model, despite having a slightly higher chi value than the dimeric model shown 
in A, shows improved fit to the low q region of the data and a more precise overlay 
with the high angstrom range of the P(r) function (F).  Likely, with slight adjustment of 
the free Ang2 fibrinogen domain and the dissociated Ang2/Tie2 subunit, an accurate 
fit could be achieved.  
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of these models by FOXS and P(r) overlay, the partial trimer shown in Figure 2.15E 
(from trimer 04305) appeared to precisely fit the experimental data in the low q range.  
The chi value for this model is 2.03, which is slightly higher than that of the dimer 
displayed in Figure 2.15A; however, based on the more accurate fit to the overall shape 
of the protein, we feel that this model better represents the protein in solution.  Likely, 
with slight adjustment of the free fibrinogen domain and the fibrinogen domain/ Tie2 
domain facing away from the coil, we could improve the fit toward 1.  Due to the endless 
permutations possible for this positioning, it is not reasonable to complete this by hand 
and our modeling program EOM is unable to perform this complicated modeling 
procedure.  However, we believe that the model shown in Figure 2.15E is a very good 
representation of our complexed proteins in solution. 
 
2.3 Structural Justification for Angiopoietin Ligand Functional Discrepancies 
 The Angiopoietin family of ligands is unique and continues to cause controversy 
within the field.  Intriguingly, few receptor tyrosine kinases have known natural 
antagonists.  However, Angiopoietin-2 is responsible for reducing Tie2 activation 
primarily at sites of active angiogenesis 55.  Alternatively, under specific conditions in the 
lymphatic system and at very high concentrations, Ang-2 activates the Tie2 receptor.  
The mechanism by which Ang-2 can switch from inactivation to activation of Tie2 has 
been widely debated.  Substantial evidence indicates that the decoy receptor Tie1 is a 
necessary component to establish Ang-2 antagonistic function and result in reduced 
Tie2 signaling 40.  Consistently, depletion of Tie1 allows for activation in response to 
Ang-2 108.  On the other hand, Angiopoietin-1 is a consistent agonist, promoting 
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Figure 2.16 Production and Characterization of Full Length Angiopoietin 
Proteins 
(A) To determine the concentration of our Angiopoietin ligands secreted into serum 
free media, we performed western blot analysis with known concentrations of rhAng-
1 from R&D to use for comparison.  (B) 500ng/mL Ang-1 and Ang-2 in serum free 
media were used to stimulate starved EA.hy926 cells treated with sodium 
orthovanadate.  Activation of Tie2 was followed using a phospho-specific antibody 
against tyrosine 992.  Our full-length recombinant Ang-1 was able to stimulate 
phosphorylation of the intracellular tyrosine kinase domain of Tie2 and verified the 
functionality of our protein. 
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clustering and cross-phosphorylation of the Tie2 intracellular split tyrosine kinase 
domains 51,109.   The two Angiopoietin ligands are highly homologous in sequence, in 
fold of the fibrinogen like receptor binding domain and in recognition of Tie2 23,49,55.  
Therefore, another area of debate has been the mechanism by which the ligands are 
able to elicit distinct functional responses despite high levels of homology. 
 As discussed in detail above, variations between the multimeric complex 
formation of Ang-1 and Ang-2 could be one mechanism used to distinguish between the 
two ligands.  Another interesting hypothesis developed previously in the lab implicates a 
surface loop adjacent to the receptor-binding region of the protein.  In Ang-1, the loop is 
composed of small, largely nonpolar residues, threonine, alanine and glycine.  In stark 
contrast, Ang-2 contains a proline and two large residues, the polar amino acid 
glutamine and charged arginine in equivalent positions.  Previously in the lab, Dr. Tom 
Seegar solved the crystal structure of Ang-2-TAG shown in blue in Figure 2.17A.  When 
compared to the crystal structure of wild-type Ang2 (shown in orange in Figure 2.17A), 
the backbone of the structures overlay with very little deviation.  Therefore, mutation of 
this loop does not affect the overall fold of the protein and any changes in function are 
most likely due to alterations in our loop of interest. 
To test whether the TAG surface loop plays a role in Angiopoietin function and to 
attempt to reverse the function of the ligands, full length protein mutants Ang2-TAG and 
Ang1-PQR were expressed in mammalian HEK293 cells.  Serum free DMEM harvested 
from stably expressing HEK293 cells was analyzed for Angiopoietin concentration as 
seen in Figure 2.16A.  To ensure proper function of the full-length recombinant proteins, 
endothelial EA.hy926 cells were stimulated using equal Angiopoietin concentrations 
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Figure 2.17 Mutating Three Surface Loop Residues Exchanges Angiopoietin 
Function 
(A) Crystal structure of wild type Ang-2 (orange) overlaid with Ang-2-TAG (blue) 
enlarged to show the mutated residues.  Interestingly, the backbone of the mutant 
shows no change in overall structure signifying proper folding of the molecule.  (B) 
EA.hy926 endothelial cells were stimulated with 500ng/mL Ang-1, Ang-2, Ang2-TAG 
(B), or Ang-1-PQR (C) and assessed for activation of the Tie2 downstream signal 
partner AKT.  Based on activation levels of the protein, it is clear that Ang-2-TAG 
behaves like the agonist Ang-1, and conversely, Ang-1-PQR behaves like Ang-2.  
Previously published 49. 
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(approximately 500ng/mL) and probed for direct activation of Tie2 using the phospho-
specific Tyrosine 992 antibody (Figure 2.16B).  Ang-1 induced robust activation of Tie2, 
while Ang-2 resulted in phosphorylation at this residue to a lesser extent.  Similarly, 
downstream activation of AKT was determined using an antibody against 
phosphorylated Threonine 308.  Here, we see a similar trend as with Tie2 
phosphorylation at Y992 with a dramatic increase in phosphorylation after stimulation 
with Ang-1 and a slight increase with Ang-2.  Interestingly, Ang-2-TAG behaves like 
Ang-1 with increased activation compared to wild-type Ang-2 (Figure 2.17B).  
Conversely, Ang-1-PQR is not able to activate the AKT signaling cascade above 
background, where wild-type Ang-1 significantly increases the phosphorylation level 
(Figure 2.17C).  Additional functional assays were explored in the PNAS paper, 
Structural Basis for Angiopoietin-1 Mediated Signaling Initiation, published in 2013 49 
including both full length receptor clustering and disruption of Tie2 interactions with the 
related co-receptor Tie1.  In all assays examined, mutation of the three surface loop 
residues from PQR in Ang2 to TAG changed the function of the context dependent 
antagonistic ligand to behave like the agonist Ang-1.  These studies have illuminated 
the importance of only three amino acids outside of the receptor binding domain on the 
mechanism of ligand function in Angiopoietin signaling. 
 
2.4 Discussion 
As a natural receptor tyrosine kinase antagonist, Angiopoietin-2 is a unique 
extracellular ligand whose mechanism of action has remained elusive 55.  Additionally, 
Ang-2 maintains high sequence and structural homology to the strict Tie2 agonist 
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Angiopoietin-1 despite eliciting opposing effects 47.  Initially, we hypothesized that a 
dimeric Angiopoietin ligand would result in Tie2 dimerization and translate to cross 
phosphorylation and activation of the Tie2 kinase domain within the cell.  Furthermore, 
Ang-2 is capable of activating the receptor under certain circumstances and therefore 
we believed activation would be achieved by similar mechanisms for both Ang-1 and 
Ang-2.  As an extension of this hypothesis, we believed that the decoy co-receptor Tie1 
acted in concert with Ang-2 to mediate deactivation of Tie2 and that this interaction 
characterized previously in the lab could explain the differences in Angiopoietin function. 
Interestingly, we have uncovered several distinctions between Ang-1 and Ang-2 
ligands through structural and biological studies.  First, the predicted free energy of the 
multimeric Ang-1 coil is inconsistent with that of Ang-2, despite occurring in homologous 
regions of the protein.  Second, the complex structure reveals Tie2 molecules pointing 
in opposite directions when in complex with Ang-2-3A9 as opposed to the ligands 
bringing the receptor into close proximity.  Finally, alterations within a small surface loop 
that differ between the ligand agonist and context-dependent antagonist can alter the 
function of the proteins.  
Coil prediction software countered our initial hypothesis that the Ang-2 coil was a 
dimer and instead predicted a stable trimer.  Ang-1, on the other hand, was determined 
to have unfavorable energy predictions for the trimeric state, yet was suggested to be 
stable as either a dimer or a pentamer.  Models were generated using dimeric, trimeric, 
tetrameric and pentameric coils for both Ang-2-3A9 protein alone and in complex with 
Tie2 (1-4).  Consistent with free energy predictions and after extensive analysis, each 
data set fit best to trimeric forms through comparison of both theoretical scattering 
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profiles and P(r) functions to the experimental data. 
As discussed considerably in the results, the multimeric Ang-2-3A9 alone 
demonstrated significant concentration dependence as the size of the protein in solution 
increased dramatically with increasing concentration.  As stated above, a trimeric model 
represented the Ang-2-3A9 protein well in solution at low concentrations.  Interestingly, 
higher order multimeric complexes through the coil (for example, tetramers or 
pentamers) did not change the overall size of the modeled protein enough to account 
for the dramatic change in size seen experimentally.  Using Monsa ab initio 
reconstruction as a guide, a model of Ang2-3A9 as a dimer of trimers was created.  
Dimerization of the trimer through the fibrinogen domain fit well to the high 
concentration data.  Logically, the experimental data collected with an intermediate 
concentration was determined to be a mixture of trimeric Ang-2-3A9 and the dimer of 
trimers.  Therefore, it appears that Ang-2-3A9 forms a trimer through the coiled-coil 
domain and that, at very high concentrations, it is capable of forming dimers of trimers 
through a low affinity interface in the fibrinogen domain.  Naturally, the next step of this 
research is to purify a similar truncation of Ang-1 and observe the multimeric state of the 
protein in solution by SAXS.  Differing multimeric states between two Angiopoietin 
molecules would be a novel mode of regulation for the Tie/Angiopoietin axis.  
Surprisingly, when first examining experimental data of Ang-2-3A9 in complex 
with Tie2 (1-4), neither dimeric nor trimeric models fit the overall size of the Ang-2-
3A9/Tie2 (1-4) protein in solution. After sequential deletion of the Tie2 (1-4) molecules 
in each of the trimeric models, it was clear that our solution consisted of a trimer of 
Ang2-3A9 complexed to only two Tie2 molecules.  Likely, there is a mechanism 
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whereby only two of the Ang-2 fibrinogen domains are accessible to Tie2 in solution.   
From the models generated, another interesting and surprising discovery was the trans 
nature of Tie2 in complex with Ang2-3A9.  Of the six best fit models for the Tie2/Ang2-
3A9 complex, all six depict the Tie2 (1-4) molecules projecting in opposite directions 
and indicate a potential secondary association between Ang-2 and Tie2 through the 
coiled coil domain.  Recently in the literature, interactions between the coiled coil 
domain of Ang-2 and Integrin molecules have been described.  This region of the 
protein has not previously been implicated in modulating interactions with other protein.  
Experiments using either surface plasmon resonance or co-immunoprecipitation with 
purified coil would be interesting to confirm the novel interaction with the Tie2 
extracellular domain.   
 Finally, characterization of the small surface loop adjacent to the receptor binding 
interface of the Angiopoietins demonstrated that three residues within the protein have a 
profound effect on ligand function.  Wild type Ang-2 contains the sequence PQR, which 
appears to regulate signaling outcomes through Tie2 in endothelial cells.  Specifically, 
Angiopoietin ligands containing the sequence TAG (the native sequence in the agonist 
Ang-1) activate Tie2 through clustering and disrupt inhibitory Tie1/Tie2 complexes as 
previously observed49.  Angiopoietin ligands containing the sequence PQR permit the 
inhibitory complex of Tie1/Tie2, do not cluster Tie2 and demonstrate decreased 
signaling through the canonical Tie2 prosurvival pathway, Akt.  Interestingly, the 
established Tie1/Tie2 interaction interface is primarily mediated by electrostatic 
interactions and therefore the charged nature of the Ang-2 loop could directly stabilize 
this interaction.  It will be interesting to see in future studies whether multimeric Ang-1 is 
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capable of bringing Tie2 extracellular domains into close proximity unlike Ang-2; 
perhaps the close proximity of the Tie2 molecules in an Ang-1 complex would prevent 
Tie1 from gaining access.   
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2.5 Materials and Methods 
Protein Expression Constructs 
Protein Purification 
For purification of secreted proteins in mammalian cells as seen in Figure 2.1. 
SECTION 1: TRANSIENT TRANSFECTION 
Cell plating for transfection (DAY 1) (Timing ~15 minutes) 
1) Split one confluent 15cm dish of HEK 293H cells with trypsin, spin at 150*g for 5 
minutes, aspirate media and resuspend cells with 5mLs of DMEM.  Add ~120uL 
of cell suspension to 2mLs of DMEM in a 6-well plate to obtain ~80% cell 
confluency within 24 hours.  
 
Transfection (DAY 2) (Timing ~25 hours; 45 minutes for transfection, 24 hour incubation, 
15 minutes media harvest and exchange) 
2) Aspirate media off cells in the 6-well plate and replace with 
Penicillin/Streptomycin free DMEM for transfection.  Store at 37°C with 5% CO2 
until liposome-DNA solution is ready. 
3) Add 2uL pcDNA3.1(+) vector control construct (1ug/uL) to 148uL OptiMEM in 
1.5mL sterile eppendorf tubes.  Repeat for pcDNA3.1-protein-Fc (neo) vector 
(1ug/uL).  Incubate tubes for 5 minutes at room temperature. 
4) In separate tubes, mix 8uL Lipofectamine2000 gently in 142uL OptiMEM.  
Repeat for all constructs.  Incubate at room temperature for 5 minutes. 
5) Add 150uL solution of Lipofectamine2000/OptiMEM to each DNA/OptiMEM 
mixture and mix by inversion (total volume of 300uL).  Incubate at room 
temperature for 25 minutes. 
6) Add 300uL DNA-liposome solutions dropwise to cells and return plate to CO2 
incubator for 24-48 hours at 37°C. 
 
Immunoprecipitation of Fc-tagged protein of interest (POI) from 6-well to check transient 
expression (DAY 3) (Timing 24 hours; 30 minute Immunoprecipitation setup, 16 hour 
incubation, 30 minute wash, 45 minute gel run, 1 hour coomassie stain and destain) 
7) Transfer 1mL of conditioned DMEM from each transfected well to sterile 1.5mL 
eppendorf tubes.   
8) If cells in 6-well plate are confluent, see next section.  If cells are subconfluent, 
aspirate antibiotic free media and replace with 2mL DMEM (containing 10% FBS 
and 1x P/S) and return to CO2 incubator until confluent. 
9) Spin conditioned media containing secreted protein at 1500*g for 5 minutes to 
remove any cell debris and transfer supernatant to a fresh sterile tube. 
10) Add 50uL of 1:1 suspension ProteinA sepharose resin: HBST to each tube of 
media using cut pipet tips.  Incubate with rotation for 2 hours or overnight at 4°C. 
11) To wash ProteinA sepharose beads, spin tubes at 9000*g for 1 minute, aspirate 
supernatant being careful not to aspirate beads, and resuspend resin in 1mL of 
HBST.   
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12) Repeat wash step once with HBST and once with HBS. 
13) Spin resin at 9000*g for 1 minute. 
14) Aspirate HBS, add 30uL of 1x SDS dyes with BME and mix.  
15) Heat samples for 1 minute at 95°C 
16)  Resolve proteins by SDS-PAGE with appropriate molecular weight markers.  
For POI-Fc run a 10% SDS-PAGE gel with low molecular weight standards at 
200V for 45 minutes with SDS running buffer. 
17)  Stain gel with coomassie brilliant blue G250 and destain.   
 
SECTION 2: COLONY SELECTION AND EXPANSION 
Colony Formation (Timing ~10-20 days; 30 minutes to split cells, 10-20 days of 
selection) 
18) Split each well of a 6-well plate into three or four 15cm dishes containing 25mLs 
of selection media (0.8mg/mL G418 in DMEM)  
For pcDNA3.1(+) hygro constructs, use 150ug/mL Hygromycin B, 10% FBS, 1x 
P/S DMEM as selection media. 
19) Change selection media on 15cm dishes every three days until colonies form 
(~10-14 days) 
 
Colony Selection (Timing ~1-2 hours) 
20) With a marker, identify 3-5 isolated colonies for expansion on each 15cm dish.   
21) Aspirate selection media.  Use 10mL PBS to rinse colonies and aspirate. 
22) Place one end of a cloning cylinder in vacuum grease and dab off excess. 
23) Position the vacuum greased end of the cloning cylinder around each identified 
colony and seal. 
24) Add 50uL of trypsin to each cloning cylinder and return to the CO2 incubator for 5 
minutes.  
25) Add 2.5mL of selection media to a sufficient number of wells in 6-well plates. 
26) Pipet trypsin up and down several times gently and transfer cells from each 
colony to one well in the 6-well plate. 
 
Colony Expansion (Timing ~2-3 weeks) 
27) Grow cells in 6-well dish to confluence (typically 3-5 days). 
28) Once confluent, repeat immunoprecipitations from step three to check clonal 
expression.   
29) Pick the two or three best expressing clones for expansion and freezing.  Discard 
others. 
30) Split cells from 6-well plate to 15 cm dish and grow until confluent. 
31) Split confluent 15cm plate into four 15cm dishes. 
32) *Freeze one 15cm plates at 80% in 3 cryovials. 
33) Split remaining confluent 15cm dishes into nine 15cm dishes (1.5 15cm plates 
per roller bottle).  Pool media from all plates, filter, add PMSF to a final 
concentration of 0.1mM, Sodium Azide to 0.2% and store at 4°C for later 
purification.  Proteins stored in this manner are generally stable for at least one 
week.  
 
99
	  
	  
	  	  
SECTION 3:  ROLLER BOTTLE SEEDING AND MAINTENANCE 
Seeding Roller bottles (Timing ~1 hour + 24 hour incubation) 
34) While colonies are expanding prepare DMEM media for roller bottles. 
35) Split nine 15cm plates and spin out trypsin.  Resuspend in 6mLs of DMEM media. 
36) Add 250mL of DMEM media for roller bottles with 20mM Hepes pH 7.4 into each 
of six roller bottles. 
37) Add 1mL of cell suspension to each roller bottle and gently swirl to mix.   
38) Place roller bottle in the roller bottle incubator at a slow speed (0.1-0.2 rpm) 
overnight at 37°C making sure that the lids are loose. 
39) After 24 hours, increase rotation speed slightly (1 rpm). 
 
Maintaining roller bottles and harvesting media (Timing ~1-3 weeks) 
40) Change roller bottle media every few days.  Monitor confluency by phase 
contrast microscopy or by eye.  Reduce serum concentration by 2.5% with every 
media change. 
41) Remove conditioned media to 400mL centrifuge tubes, balance and spin at 
5000*g for 20 minutes in a Sorvall SLA 3000 rotor to remove any cellular debris. 
42) Filter supernatant through a large chromatography tube with a glass frit.  
43) Add PMSF to a final concentration of 0.1mM, and Sodium Azide to 0.2%. 
44) Store at 4°C until ready to proceed with purification process. 
 
SECTION 4: PURIFICATION 
Purification of Fc tagged protein (Timing ~1-3 days) 
45) Pack 5-20mLs of ProteinA sepharose in a Pharmacia XK16 column depending 
on expression and number of roller bottles.   
46) Attach column to Akta and wash with 2 column volumes of water. 
47) Wash pump A into HBS and Pump B into 100mM Glycine pH 3, 150mM NaCl 
buffer. 
48) Wash column with 5 column volumes of HBS. 
49) Load media onto column using injection valve or P-960 Sample pump at 1-2 
mL/min.   
50) Wash with 10 column volumes of HBS until UV signal stabilizes and resin is clear.  
Collect flow through to check on a gel. 
51) Add 100uL of 1.5M Tris pH 8.8 buffer to each well needed of a 96-well deep well 
plate to collect elution fractions. 
52) Elute protein with 2 column volumes glycine buffer through Pump B.  Collect 1mL 
fractions in the 96 well deep well plate with neutralizing buffer already present. 
53) Wash column back into HBS. 
 
Checking Purification (Timing ~2 hours) 
54) Run a 10% SDS page gel aiming for 5-10ug of protein at the peak based on the 
chromatograph A280 to analyze fractions and flow through. 
55) Stain with coomassie brilliant blue G250 and destain. 
 
Concentrate Protein (~40 minutes) 
56) Pool fractions containing POI-Fc. 
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57) In a 4mL 10kDa MW cut off Amicon Ultra concentrator, spin pooled fractions at 
3000*g for 20 minutes in a swinging bucket centrifuge. 
58) Repeat spin until total pool volume is reduced to ~550uL. 
 
Size Exclusion Chromatography (Timing ~3 hours) 
59) Wash a SD200 10/300 GL size exclusion column into water and then HBS (with 
10% glycerol if not proceeding with cleavage step) according to manufacturers’ 
instructions at ~0.5mL/min. 
60) Filter protein solution through a 0.2um Millipore spin filter at 4000*g for 5 minutes 
4°C. 
61) Save a small aliquot of concentrated Fc tagged protein to use as a loading 
control on the subsequent SDS-PAGE gel. 
62) Load 500uL of concentrated POI-Fc onto column and run in HBS collecting 
0.5mL fractions in a deep well 96-well block. 
63) Check fractions by SDS-PAGE. 
64) Repeat concentration of POI-Fc containing fractions in a fresh Amicon 
concentrator to 1-10mg/mL in aliquots of 500uL. 
*If Fc tagged protein is desired, purification is complete and proceed to step 86 for 
storage.  To remove the Fc tag, continue to next section. 
 
SECTION 5: CLEAVAGE 
Cleavage (Timing 16 hours incubation + 1 hour) 
65) Cleave desired amount of protein with 1 unit Thrombin per 1mg of target protein 
overnight at room temperature (in HBS pH 7.4 off SEC). 
66) Allow a small control protein sample to sit at room temperature without Thrombin 
to observe any precipitation and contaminate protease activity by SDS-PAGE. 
67) Check uncleaved and cleaved samples by SDS-PAGE and coomassie staining. 
 
Separation of Fc tag from POI (Timing ~2 hours) 
68) Wash a small ProteinA Sepharose column with several column volumes of dH20. 
69) Wash Pump A into HBS and Pump B into Glycine Elution Buffer.   
70) Wash column with several column volumes of HBS at 1mL/min.  
71) Filter protein solution through a 0.2um Millipore spin filter at 4000*g for 5 minutes 
4°C. 
72) Reserve a load sample for subsequent SDS-PAGE analysis. 
73) Load cleaved sample onto the ProteinA sepharose column slowly (0.5mL/min) to 
allow Fc tag to bind and separate from flow through.  (Be aware of columns max 
protein load) 
74) Collect 0.5mL fractions of the flow through containing cleaved POI. 
75) Elute cleaved Fc tag and any remaining uncleaved protein with Pump B (Glycine 
Elution Buffer) at 1mL/min and collect 1mL fractions in deep well 96-well plate 
already containing 100uL 1.5M Tris pH 8.8 buffer. 
76) Wash column with 10 column volumes of HBS. 
77) Wash column into dH20 and store in 20% EtOH. 
78)  Check fractions by SDS-PAGE and coomassie staining. 
 
101
	  
	  
	  	  
Concentrate cleaved POI (Timing ~1 hour) 
79) Pool fractions containing cleaved POI from ProteinA flow through. 
80) Concentrate to ~550uL in a fresh Amicon concentrator. 
 
Final Size Exclusion Purification Step (Timing ~3 hours) 
81) Filter protein solution through a 0.2um Millipore spin filter at 4000*g for 5 minutes 
at 4°C. 
82) Save 5ug as a loading control for subsequent SDS-PAGE analysis. 
83) Load 500uL on SD200 10/300 GL column equilibrated in HBS (or 20mM bis Tris 
propane pH 7.0, 150mM NaCl for setting crystallization trials) and elute at 
0.5ml/min. 
84) Collect 500uL fractions in a 96 well deep well plate.  
85) Run fractions on a SDS-PAGE gel and coomassie stain. 
 
Concentrate and Freeze Pure Protein (Timing ~ 1 hour) 
86) Based on results of SDS-PAGE, pool fractions containing POI. 
87) Concentrate POI and pool to 1-10mg/mL using a fresh Amicon Concentrator. 
88) Aliquot protein stock to a maximum volume of 500uL protein solution per tube. 
89) For cryopreservation, add glycerol to a final concentration of 10%.  Alternatively, 
do not add glycerol if protein will be used for transmission electron microscopy. 
90) Flash freeze protein aliquots in liquid nitrogen and store at -80°C. 
 
Transmission Electron Microscopy 
Briefly, protein eluted from the size exclusion column was diluted in Hepes 
buffered saline and incubated on charged carbon coated grids.  Grids overlaid with 
protein were washed with water and negatively stained using uranyl formate.  Imaging 
by Transmission Electron Microscopy was completed with the help of our collaborators 
Dr. Tom Walz and Dr. Montserrat Samso.  
 
SAXS Sample Preparation 
 Single protein samples were eluted in HBS with 2% glycerol from the SD200 
10/300 GL column as described in steps 81-85 of the protein purification section.  Buffer 
eluted from the column before the void volume was used for buffer control samples and 
for dilution of the protein to create varying concentration samples.  Ang2-3A9 / Tie2(1-4) 
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complex was prepared on ice and incubated for one hour with excess molar Tie2(1-4) 
before running over the SD200 10/300 GL column in 2% glycerol + HBS.  Two 0.5mL 
fractions corresponding to the leading edge of the shifted complex peak were 
concentrated and sent for SAXS analysis at the Lawrence Berkeley National Labs 
SIBYLS Beamline. 
 
SAXS Data Analysis 
 Initial SAXS analysis to determine Rg, Volume, and Dmax values was performed 
in Scatter (BioIsis/ SIBYLS Beamline Lawrence Berkeley National Labs).  For modeling, 
the FASTA sequence of Ang-1 and Ang-2 was provided to Coils in the ExPaSy 
Bioinformatics Resource Portal to generated predicted regions for the coiled coil110.  
Based on the results from Coils, residues 77 – 267 of Ang-1 and 71- 264 of Ang-2 were 
used in CCBuilder to generate predicted free energy values and PDB files of coils 
ranging from dimers to heptamers.  The truncated coil sequence of Ang-2-3A9 from 
residues 174 – 264 was also evaluated. Subsequent modeling was performed using the 
ATSAS suite online servers for EOM PDB generation with the coil PDBs, the Ang2 
fibrinogen domain crystal structure or Ang2 fibrinogen domain in complex with Tie2 (1-
4) for the complex data set and full protein sequence as input.  Output PDBs were 
evaluated based on fit to experimental data using the FOXS webserver111 and P(r) 
function overlay in Scatter.  
 
Tie2 Activation Assays 
For analysis of Tie2 activation in endothelial cells, EaHy926 cells were grown to 
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post-confluency and serum starved for 4 hours prior to the addition of 500ng/ml full 
length Angiopoietin-1, -2, -1-PQR or -2-TAG.  Fifteen minutes prior to ligand addition, 
sodium orthovanadate (Sigma) was added to 1mM in the culture medium.  Thirty 
minutes following ligand addition, cells were harvested in NP-40 lysis buffer (20mM 
Hepes pH 7.4, 150mM NaCl, 1% NP-40, 1mM EDTA, 1mM PMSF, 0.1% Aprotinin 
(Sigma)) in the presence of 1mM sodium orthovanadate and subjected to western 
blotting.  Endogenous Akt was analyzed with anti-Akt (Cell Signaling) or anti-phospho-
specific Akt T308  (Cell Signaling).  
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Chapter 3 
Physical Association between the Tie/Angiopoietin Axis and Endothelial Integrins 
 
As discussed briefly in the previous chapter, co-receptor interactions between 
Tie1 and Tie2 play an important role in regulating Tie2 activation and endothelial cell 
physiology 40,108.  Similarly, Integrin adhesion receptors are demonstrated binding 
partners of the Tie2 RTK, though many aspects of the association remain unclear.  
Integrin molecules interact with multiple growth factor receptors at the cell surface to 
regulate intracellular signaling cascades 68.  Of the nine integrin molecules present in 
endothelial cells, α5β1 and αVβ3 are essential for modulation of the angiogenic response.  
Integrins αV and α5 knockout mice phenocopy angiogenic defects of the Tie2 and 
Angiopoietin-1 deficient mice, suggesting potential crosstalk and interactions in vivo 
17,42,78.  Though crosstalk between Integrins and the type 1 receptor tyrosine kinase Tie2 
has been previously examined, various groups have reported conflicting results.   For 
example, Cascone et al. demonstrate that α5β1, but not αVβ3, constitutively associates 
with Tie2 in human umbilical vein endothelial cells (HUVECs) in the presence of native 
ECM 102.  Alternatively, Thomas et al. found αVβ3 in complex with Tie2, though this 
interaction required a Tie2 ligand (either Ang-1 or Ang-2) 103,104.  Interestingly, 
compensation between the two Integrin molecules has made it difficult to elucidate 
specific interactions at the endothelial cell surface.    
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3.1 Tie1 and Tie2 interact constitutively with the endothelial Integrins α5β1 and 
αVβ3  
To clarify these conflicting results, we assessed the potential of a Tie receptor to 
associate with endogenous αVβ3 in confluent EA.hy926 endothelial cells.  Surprisingly, 
by co-immunoprecipitation, we reveal a constitutive interaction between αVβ3 and a Tie 
receptor using a pan specific Tie receptor antibody (Figure 3.1A and B).  In contrast to 
earlier reports, protein association does not require stimulation by either Angiopoietin 
ligand, nor is complex formation altered after 30 minute incubations with Ang-1 or Ang-2 
(Figure 3.1A).  Additionally, an interesting αV reactive band is observed when cells are 
incubated with the Tie2 agonist Ang-1 prior to lysis and immunoprecipitations, but not 
when incubated in the presence of the context dependent antagonist Ang-2.  Therefore, 
the Angiopoietins do not appear to affect the physical association of the Ties and 
Integrins; however, the ligand Ang-1 may affect the processing of αV and potentiate 
downstream signaling.  
Unlike Angiopoietin ligand stimulation, the Integrin ligand fibronectin does 
increase Integrin/Tie complex formation in a similarly executed experiment (Figure 3.1B).  
Here, EA.hy926 endothelial cells were plated on either PBS treated or fibronectin 
treated plates for 24 hours before stimulation with the Angiopoietin ligand Ang-1.  The 
dramatic increase seen in immunoprecipitated αV protein levels after cells were plated 
on fibronectin indicates that fibronectin may play a direct role in modulating the contact 
between the two receptor families. Interestingly, the small αV structure observed in Ang-
1 stimulated cells is no longer present when the cells have been plated on fibronectin as 
seen in Figure 3.1B.  Therefore, these extracellular ligands clearly have differing effects 
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Figure 3.1 Co-immunoprecipation of endogenous αv with Tie receptor in 
EA.hy926 endothelial cells.  (A) Cells were serum starved and then treated with 
either vehicle control (PBS), 500ng/mL rhAng1 or 500ng/mL rhAng2 for 30 minutes 
before lysis with NP40 lysis buffer.  αv co-precipitated under all stimulation conditions 
tested when lysates were incubated overnight with C20 antibody against Tie2.  (B) 
Wells of a 6-well plate were treated with 1mL PBS or 5µg/mL rhFibronectin overnight. 
Endothelial cells were plated and grown to confluence, serum starved and treated 
with vehicle control or 500ng/mL Ang-1 prior to harvest.  Lysates were 
immunoprecipitated overnight with anti-Tie2 antibody or a non-specific IgG (NS-IgG).  
Western blot analysis demonstrates that αv immunoprecipitates with Tie2 under all 
conditions tested and fibronectin increases the amount of co-precipitating integrin.  
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on receptor complex formation, where fibronectin can directly influence the quantity of 
complex formed while the Angiopoietins cannot.  The results also indicate that the 
Angiopoietins may instead have a signaling effect through the complex to be discussed 
in Chapter 4.  
 
3.2 Tie1 and Tie2 receptors associate with α5β1 / αVβ3 through their 
extracellular domains  
Next, we wished to elucidate specific receptors within our Tie/Integrin signaling 
complex found in endothelial cells.  In Figure 3.1, we employed an intracellular kinase 
domain specific Tie antibody to limit interference with interactions potentially occurring 
through the extracellular domains.  However, this antibody recognizes both Tie2 and its 
highly homologous inhibitory co-receptor Tie1 (39% amino acid conservation).  Though 
Tie1 is considered an orphan receptor, both molecules contain a similar IgG rich 
extracellular domain (responsible for ligand recognition in Tie2), a single pass 
transmembrane domain, and an intracellular tyrosine kinase domain that specifically 
shares 76% homology 16.  To more precisely differentiate between components of the 
Integrin/Tie complex, full-length Tie1, Tie2, and Integrin receptors were tagged with 
either HA, myc, or flag tags, respectively, and transiently transfected into HEK293 cells.  
This cell line lacks the endothelial specific Tie1 and Tie2 proteins, yet does express low 
levels of α5β1 and αVβ3 Integrins.  Similarly, it is impossible to rule out the presence of 
fibronectin in the media or its being secreted by the cells themselves.  Nonetheless, 
Integrin heterodimers were immunoprecipitated from transiently transfected, confluent 
cells, and probed for association with Tie1 or Tie2, using anti-HA or anti-myc antibodies, 
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Figure 3.2 Co-immunoprecipitation of α5β1 or αvβ3 with Tie receptors from 
transiently transfected HEK293 cells. (A) Full-length integrins α5β1 (B) or αvβ3 were 
immunoprecipitated with anti-flag antibody, while co-precipitating HA-tagged Tie1 
receptor or myc-tagged Tie2 receptor were detected by western blot using anti-HA or 
anti-myc antibodies, respectively.   
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respectively.  Surprisingly, both Tie1 and Tie2 formed complexes with α5β1 (Figure 
3.2A) and αVβ3 (Figure 3.2B) in HEK293 cells in the absence of Ang-1, Ang-2 or specific 
fibronectin stimulation.  The unexpected and novel interaction discovered between Tie1 
and endothelial Integrins may have significant implications in endothelial cell stability 
and angiogenesis.   
Having identified and validated a physical interaction between the Tie receptors 
and α5β1/ αVβ3, we moved to elucidate sites or domains responsible for modulating this 
association.  Based on fibronectin’s ability to increase association, we postulated an 
interaction interface using their respective ectodomains.  To verify this hypothesis, the 
intracellular tyrosine kinase domain of the Tie receptors was replaced with fluorophore 
variants of GFP and transfected into HEK293 cells (Figure 3.3).  Tie fluorophore 
constructs retain the full ectodomain and transmembrane domain of the protein and are 
functionally active as demonstrated by Tie2-mCFP’s ability to cluster in response to its 
agonist, Ang-1.  Therefore, Tie2-mCFP clustering mimics full-length receptor behavior.  
Through this experiment we revealed that Tie1 and Tie2 fluorophore constructs lacking 
their respective kinase domains readily associated with both full-length flag tagged α5β1 
(Figure 3.4A) and αVβ3 (Figure 3.4B) integrin proteins.  Interestingly, the interaction 
occurs within the extracellular or transmembrane portions of the Tie receptors.   
 
3.3 Fibronectin increases complex formation in vivo between Tie2 and α5β1 as 
demonstrated by FRET microscopy 
Förster (Fluoresence) Resonance Energy Transfer (FRET) microscopy is a 
particularly powerful approach for examining real time protein-protein interactions in vivo.  
112
	  
	  
	  	  
  
Figure 3.3 Schematic representation of the Tie1, Tie2, and integrin constructs 
used in Figure 4.  pcDNA3.1 vector backbones were used to express Tie2-mTQ, 
Tie1-sYFP2 and Integrin-DDK constructs in HEK293 cells.  These Tie receptor 
variants contained the extracellular Ig, EGF, and fibronectin repeats as well as the 
transmembrane domain of the native Tie proteins.  The intracellular kinase domains 
of Tie2 and Tie1 were replaced with either the mTQ or sYFP2 fluorophores, 
respectively.  Full length integrin protein was flag tagged on the C-terminal tails of 
both the α and β subunits.   
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Figure 3.4 Co-immunoprecipitation of α5β1 and αvβ3 with the extracellular 
domains of the Tie receptors.  A similar experiment to Figure 3.2 was performed 
using the constructs described in Figure 3.3.  HEK293 cells were transfected with 
Tie1 and Tie2 receptor fluorophore fusion constructs in which the intracellular 
tyrosine kinase domains were replaced with the GFP analogues sYFP2 and mTQ 
variants, respectively. Immunoprecipitation was performed using anti-DDK against 
the full length flag tagged integrin proteins (A - α5β1 and B - αvβ3).  Co-precipitating 
Tie1 and Tie2 fusion proteins were detected by western blot with anti-GFP 
antibodies.   
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FRET allows users to push resolution limits of light microscopy imposed by the 
numerical aperture of the objective by measuring the non-radiative energy transfer from 
a donor fluorophore to an acceptor fluorophore.  For FRET to occur, several criteria 
must be met; the donor’s emission wavelength must significantly overlap with the 
excitation wavelength of the acceptor molecule, the dipoles of the fluorophores must be 
arranged in favorable orientations, and the donor and acceptor must be in close 
proximity (within ~10nm of one another).  There are several distinct techniques available 
to measure the existence of FRET including acceptor photobleaching, sensitized 
emission microscopy and FLIM-FRET 112.  Our lab has employed all of these 
procedures to examine important cell surface contacts that proved otherwise difficult to 
characterize.   
Thus, to confirm fibronectin’s role on Tie interactions in vivo, we used the 
knowledge that Tie2 interacts with α5β1 through its extracellular domain in a live cell 
FRET assay.  Briefly, HEK293 cells were plated on either PBS treated or fibronectin 
coated 35mm glass bottom dishes for use with the inverted microscope, transfected 
with fluorophore fused receptor constructs using Lipofectamine 2000 and imaged when 
confluent between 24 and 48 hours.  First and foremost, using both wide-field and 
confocal microscopy, we were able to observe membrane localization of our fusion 
proteins α5-YFP, β1-mCherry, and Tie2-mTurquoise (mTQ).  Based on the work of Kim 
et al. as depicted in Figure 3.5, these constructs were engineered to replace the 
cytosolic domains of our receptors with the indicated GFP variants while leaving the 
extracellular domains intact 92.  The fluorophore variants of CFP (mTQ) and YFP 
(mYFP/sYFP2) were used for their improved solubility, increased intensity, and in the 
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Figure 3.5 Cartoon depictions of a FRET interaction between the Tie2 receptor 
and either the bent or active form of an Integrin adhesion molecule.  If the 
receptor’s extracellular domains are within close enough proximity (~10nm), the 
fluorophores will be capable of non-radiative energy transfer from the donor to the 
acceptor molecule.  Fluorescence resonance energy transfer is monitored in this 
study through sensitized emission wide-field microscopy and fluorescence lifetime 
measurements as detailed in the text.  Here, a Tie receptor (green) fused to a cyan 
fluorescent protein molecule is depicted as the donor and the acceptor molecule is 
fused to the α subunit (grey) of the integrin in either the bent inactive conformation or 
the extended active conformation.  The β subunit (blue) is fused to mCherry in order 
to monitor expression and localization of the protein. The schematic and experiment 
were both modified from Kim, et al. 2003 92. 
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case of mTQ, a longer lifetime to aid in FLIM-FRET measurements113,114.  The β subunit 
of the integrin molecule fused to mCherry was used to monitor expression and 
localization of the protein but was not considered as a variable in FRET calculations.  
Additionally, co-transfection of the β subunit was necessary for protein stability and 
proper membrane localization of the α  subunit. 
Sensitized emission FRET measures the increase in acceptor emission in 
response to excitation of the donor molecule.  A schematic of our experimental design is 
shown in Figure 3.5.  To validate our wide field sensitized emission FRET system, Tie1-
sYFP2/Tie2-mTQ was used as a positive control, yielding an average FRET efficiency 
of 32.9% +/- 5.5% standard error on a Zeiss Observer Z.1 microscope, comparable to 
previously published values from the lab.   As a negative control, the unrelated receptor 
PlexinA1 was fused to YFP and cotransfected with Tie2-mTQ into HEK293 cells yielding 
a low FRET efficiency of 5.8% +/- 0.4% for non-interacting receptors overexpressed on 
the cell surface.  Our experimental data for Tie2-mTQ and α5-YFP demonstrates that 
fibronectin coating does significantly increase association between Tie2 and α5β1 from 
17.4% +/- 2.1% to 27.7% +/- 2.5% (Figure 3.6 and 3.7).  Both proteins were properly 
localized to the cell membrane with and without fibronectin coating as can be see in 
Figure 3.6.  
 To confirm our sensitized emission experiments, fluorescence lifetime 
measurements were obtained using a time correlated single photon counting system 
(TCSPC) (Becker and Hickl) on a Zeiss Meta 510 with a mode locked 80MHz 
Ti:Sapphire laser.  Fluoresence lifetime measurements calculate the duration of the 
fluorophore’s excitation.  Several environmental factors capable of altering a molecule’s 
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Figure 3.6 Sensitized Emission Fluorescence Resonance Energy Transfer 
Efficiency images characterizing the α5β1/Tie2 interaction. All transiently 
transfected live-cell images were obtained using a Zeiss Observer Z.1 incubated 
wide-field microscope. CFP, YFP, and mCherry images were excited using LEDs 
corresponding to 420, 505, and 590nm, respectively. FRET efficiency images and 
values were acquired using the Pfret software129. Tie1/Tie2 FRET was used as a 
positive control as verified in Seegar et al, 2010 40. The unrelated receptor PlexinA1-
Tie2 was used as a negative control. α5β1/Tie2 transfections were tested to 
determine FRET efficiencies between the α5 and Tie2 receptors in the presence or 
absence of 5µg/mL fibronectin. β1 integrin was cotransfected to ensure α5 stability 
and localization to the membrane.  
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Figure 3.7 Graphical depictions of the Sensitized Emission FRET efficiencies 
for α5β1/Tie2.  FRET efficiency values determined using Pfret software were 
averaged and depicted in the graph ± SEM.  Our positive control, α5β1/Tie2 – 
fibronectin and α5β1/Tie2 + fibronectin were all significantly above the negative 
control value of PlexinA1-YFP/Tie2-mTQ using the statistical program JMP 11 Pro.  
Furthermore, the addition of fibronectin significantly increased complex formation 
between α5β1 and Tie2 proteins. 
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intrinsic lifetime are the pH, ion concentration, and availability of an acceptor molecule 
for energy transfer.  Therefore, it is possible to calculate FRET by measuring alterations 
in the lifetime of a donor molecule if conditions between samples are held constant.  As 
depicted in the Jablonski diagram in Figure 3.8B, the presence of an acceptor molecule 
will decrease the overall lifetime of the donor molecule due to the non-radiative energy 
transfer between fluorophores 115. The same transfected samples used in sensitized 
emission experiments discussed above were subjected to fluorescence lifetime 
measurements.  Minimum laser power at 810nm excited mTurquoise and did not 
appreciably contribute to fluorophore bleaching.  Tie2-mTQ alone intensity plots over 
time obtained from repetitive laser pulses fit to a single component exponential decay 
curve from which a lifetime of 3.09ns was calculated.  When acceptor fluorophore YFP 
variants were introduced into the cells as fusions with either the positive control Tie1, 
negative control PlexinA1 or α5, the decay of the lifetime fit to a two-component model.  
The slow component represents the population of donor molecules not currently 
associating with an acceptor molecule, while the fast component determines the lifetime 
of donor molecules actively transferring energy to an acceptor.  With the slow 
component fixed to donor alone control values, a reduced mean lifetime of 2.39ns was 
observed after addition of Tie1-sYFP2 indicating energy transfer from the donor to 
acceptor due to close proximity of the molecules.  When PlexinA1 was introduced to the 
system, we did not see a substantial decrease in the lifetime to 3.00ns.  Alternatively, in 
the presence of α5-YFP and in agreement with our sensitized emission experiments, the 
lifetime decreased to 2.55ns when HEK293 cells were plated on PBS treated plates.  
Addition of 5µg/mL fibronectin protein coated on the imaging dishes, reduced the 
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Figure 3.8 FLIM-FRET Analysis of α5β1/Tie2 interactions.  (A) FLIM-FRET 
measurements were conducted on the same transfections used for sensitized 
emission measurements.  Lifetime values described are the peak values of the fast 
component after the slow components were fixed to donor alone control.  Tie2-mTQ 
alone: 3.09ns; Tie2-PlexinA1-YFP: 3.00ns; Tie2-mTQ/Tie1-sYFP2: 2.39ns; Tie2-
mTQ/α5-YFP/β1-mCherry: 2.55ns; Tie2-mTQ/α5-YFP/β1-mCherry in the presence of 
5µg/mL fibronectin: 2.5ns.  Images and decay matrix analysis was performed in 
SPCImage.  (B) Jablonski diagram describing lifetime values as related to 
Fluorescence Resonance Energy Transfer. 
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lifetime further to 2.50ns corroborating the increase in FRET efficiency seen by 
sensitized emission (Figure 3.8).   Increased FRET efficiency in the presence of 
fibronectin implicates the activated and extended form of the integrin molecule in 
complex formation with Tie2. 
 
3.4 Purified complex components reveal that Tie2 can out-compete Tie1 for 
Integrin binding 
To define precise requirements for integrin association, we utilized highly purified 
components in an in vitro co-precipitation assay.  Numerous ectodomain variants of Tie, 
Integrin and Ang ligands were purified from mammalian HEK293 cells.  Briefly, proteins 
were expressed as IgG Fc fusion proteins from stably transfected cells, purified via 
affinity chromatography on ProteinA Sepharose and in some cases cleaved from their 
tag via thrombin or TEV proteolysis.  The full procedure for purification from mammalian 
cells is depicted in Figure 2.1 and representative purified components were separated 
by 10% SDS-PAGE and stained with Coomassie Brilliant Blue (Figure 3.9).  In order to 
demonstrate that the novel interaction between Tie1 and α5β1 occurs directly and in the 
absence of other cellular components, highly purified α5β1 extracellular domain was 
incubated with Tie1 (1-4)-Fc.  Tie1 (1-4)-Fc is equivalent to the ligand binding domain of 
Tie2 designated Tie2 (1-4), which contains the membrane distal Ig and EGF domains of 
the extracellular domain.  After a brief incubation, Tie1 (1-4)-Fc was precipitated from 
solution using ProteinA Sepharose beads and resolved by SDS-PAGE.  In the presence 
of purified Tie1 (1-4)-Fc, α5β1 is efficiently precipitated suggesting a strong interaction 
(Figure 3.10).  In an effort to elucidate the effect of Tie2 on a Tie1/α5β1 complex, Tie2 
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Figure 3.9 Representative Secreted Pure Proteins from HEK293 cells.  Several 
purified and cleaved protein products used in the following co- precipitation assays 
are presented by coomassie stained SDS-PAGE.  Representative molecular weights 
shown in kDa are displayed from the Biorad low molecular weight marker.   
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(1-4) was co-incubated with Tie1 (1-4)-Fc and α5β1 and analyzed as above (Figure 3.10).  
Surprisingly, increasing Tie2 effectively competes with Tie1 for α5β1 binding, thereby 
suggesting that an overlapping interface mediates the interaction.  By using purified 
components, we have demonstrated that additional cellular components are not 
required for complex formation, further established that the Tie Ig and EGF domains are 
sufficient for Integrin recognition, and demonstrated that Tie1 and Tie2 use similar 
interfaces for Integrin contact. 
 
3.5 Fibronectin dramatically influences the direct interaction between Tie2 and 
α5β1, but not Tie1 
In a similar experiment, purified Tie1 (1-4)-Fc was incubated with α5β1 in the 
presence and absence of purified human fibronectin from plasma.  The amount of 
integrin precipitated did not depend on the addition of fibronectin protein (Figure 
3.11B/C).  Similarly, when the experiment was conducted with a fragment of the 
fibronectin protein, which includes the integrin binding RGD sequence termed 
fibronectin 9-10, the amount of precipitated protein was again unchanged (Figure 
3.11C).  Alternatively, human full length fibronectin did dramatically increase the amount 
of complex formed between Tie2 (1-4)-Fc and the Integrin α5β1 (Figure 3.11A).  
Interestingly, the fibronectin 9-10 purified protein did not stabilize the complex, 
indicating that a region outside of this fragment in the fibronectin protein is required to 
increase binding between Tie2 and α5β1.  As realized in our previous FRET experiments 
and seen here, fibronectin is not essential for binding to occur because a small quantity 
of complex is visible between the Integrin and Tie2 with no fibronectin present.   
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Figure 3.10 Direct association between Tie1 and Integrins is outcompeted by 
Tie2 pure protein. 
Purified Tie1 (1-4)-Fc protein was incubated with purified α5β1 ectodomain in the 
presence or absence of an increasing amount of Tie2 (1-4).  Following precipitation 
of Tie1 (1-4)-Fc with Protein-A Sepharose, proteins were subjected to western 
blotting with α5-specific antibodies. α5β1 readily precipitates with Tie1, demonstrating 
that the 3-Ig domains and 3-EGF repeats are sufficient for α5β1 recognition.  
Furthermore, Tie2 (1-4) effectively competes with Tie1 for integrin binding, 
suggesting a shared binding interface of Tie1 and Tie2 on the Integrin molecule.  
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Figure 3.11 Fibronectin substantially enhances Tie2/Integrin complex 
formation, but not Tie1.   (A) Purified Tie2 (1-4)-Fc protein was incubated with 
purified α5β1 ectodomain protein in the presence or absence of either full-length or 
recombinant fibronectin containing only the 9th and 10th fibronectin type-III repeats (9-
10). Following precipitation of Tie2 (1-4)-Fc with Protein-A Sepharose, proteins were 
electrophoresed by SDS-PAGE, transferred to nitrocellulose, and Tie2 was briefly 
visualized with Ponceau S prior to western blotting with α5-specific antibodies. The 
α5β1 ectodomain readily precipitates with Tie2, although the addition of full-length 
fibronectin, but not recombinant (9-10), greatly enhances the Tie2/integrin interaction. 
(B) As in Panel A except that Tie1 (1-4)-Fc is incubated with purified α5β1 ectodomain 
protein in the presence or absence of full-length fibronectin. Unlike the experiments 
shown in A, fibronectin does not significantly enhance the Tie1/integrin interaction. 
(C) Tie1 (1-4)-Fc protein was assayed similarly to the experiment shown in Figure 
3.11B.  In addition to human fibronectin purified from plasma, recombinant fibronectin 
truncation termed fib 9-10 was assessed for its ability to affect the association 
between Tie1 and α5β1.  Similarly to fibronectin from plasma, rhfib 9-10 also did not 
affect the interaction. 
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3.6 Ang-1 directly associates with both α5β1 and αVβ3 in the absence and 
presence of Tie2 
Several studies illustrate the Angiopoietin ligands’ influence on Integrin 
molecules primarily using integrin blocking antibodies in endothelial cells.  Curiously, 
Angiopoietin effects have also been observed in non-endothelial cell types including 
cardiomyocytes, breast cancer cells, and neurons that lack the endothelial specific 
primary receptor for the Angiopoietin ligands, Tie2.  To evaluate the association of 
Integrins with the Ang ligands, purified receptor binding domains of Ang-1-Fc and Ang-
2-Fc were incubated at 4 degrees overnight with extracellular portions of the Integrin 
molecules α5β1 (Figure 3.12A) and αVβ3  (Figure 3.12B) either in the absence or 
presence of the Tie2 ectodomain.  In agreement with our in vivo experiments to be 
discussed in greater detail in Chapter 4, the Ang-1-FD-Fc fusion protein, but not Ang-2, 
associates with Integrin.  Surprisingly, the interaction occurs at a similar level in both the 
presence and absence of Tie2.  To validate that both Ang ligands are functionally active, 
we demonstrate their ability to precipitate with the Tie2 extracellular domain.   
 
3.7 Fibronectin does not affect the ability of Ang-1 to bind to α5β1 
As was demonstrated in the previous figure, Ang-1, but not Ang-2, binds 
efficiently to the α5β1 extracellular domain.  To determine whether the Integrin ligand 
could influence Ang-1 and α5β1 association, full length human fibronectin was added to 
incubating Integrin and Fc-tagged Angiopoietin-1 fibrinogen domain protein.   As seen in 
Figure 3.12C, fibronectin did not change the amount of α5β1 precipitated with Ang-1-Fc 
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Figure 3.12 Direct association between the Ang-1 fibrinogen-like domain and 
α5β1 and αvβ3. (A) The Ang-1 and Ang-2 fibrinogen domains were expressed and 
purified as Fc fusion proteins, and incubated with purified α5β1 in the presence or 
absence of human fibronectin.  Following precipitation of Ang-Fc proteins with 
Protein-A sepharose, proteins were electrophoresed by SDS-PAGE, transferred to 
nitrocellulose, and Ang’s were briefly visualized with Ponceau S prior to western 
blotting with α5-specific antibodies. The α5β1 ectodomain readily co-precipitates with 
Ang-1, but not with Ang-2. Fibronectin does not appear to significantly influence the 
Ang-1/Integrin interaction. (B) As in A, except that the experiment was repeated in 
the presence or absence of the Tie2 ectodomain and precipitating proteins were 
visualized with Tie2 and β1-specific antibodies (α5 migrates at the same position as 
Tie2 and, therefore, α5-antibodies could not be used). The Tie2 ectodomain readily 
precipitates with both the Ang-1 or Ang-2 fibrinogen domain, while α5β1 only 
precipitates with Ang-1, which is not significantly affected by the presence or absence 
of Tie2. (C) Similar to the experiment in B with the purified ectodomain of αvβ3 protein 
incubated with either Ang-1-FD-Fc or Ang-2-FD-Fc. Precipitating αvβ3 was visualized 
with antibodies specific to β3. 
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and additionally did not induce the formation of an interaction between Ang-2-Fc and 
the Integrin molecule.  Therefore, it does not appear that the ligands cooperatively bind 
to the Integrin ectodomain. 
 
3.8 Conclusions 
 Integrin / Tie2 crosstalk has previously been explored in the literature; however, 
conflicting results have been described.  In some cases an interaction with α5β1 was 
described, while in several other papers the Integrin αVβ3 was implicated as the Tie2 
binding partner 102–104.  Functional overlap of αVβ3 and α5β1 is clear, based on analysis 
of knockout mice 78.  Though both Integrins were demonstrated to affect vascular 
development prior to the generation of these mice, neither the α5 nor the αV individual 
knockouts showed consistent defects in the progression of the vasculature 73.  
Interestingly, a double knockout mouse of α5 and αV was unable to progress past the 
onset of angiogenesis, perishing at E14.5 similar to the Tie2 and Angiopoietin-1 
knockout mice 19,51,78.  The ability of these integrins to compensate for one another has 
made characterization of their functional interactions difficult.   
 Using multiple powerful biochemical and biophysical techniques, we 
demonstrated that Tie2 can interact with both implicated endothelial Integrins, αVβ3 and 
α5β1.  The interaction is direct and does not require additional cellular components as 
seen in a highly purified system.  Surprisingly, the Angiopoietins, physiological ligands 
for Tie2, do not influence complex formation in our assays. However, the Integrin ligand 
fibronectin does increase the quantity of complex formed both in vitro in isolation and in 
a live cell FRET based assay.  There are two possible mechanisms by which fibronectin 
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influences the Tie/Integrin complex.  First, fibronectin may cause the Integrin molecule 
to adopt a conformation that is amenable to complexation with the Tie2 receptor.  The 
N-terminus of each Integrin subunit mediates heterodimer formation of the α and β 
subunits and creates a head domain responsible for association with the extracellular 
matrix component ligand; ligand specificity varies based on the combination of subunits. 
Functional regulation of the Integrins is controlled by large conformational shifts in the 
extracellular domain forming either a significantly bent inactive conformation in which 
2000A2 of surface area is buried or an extended conformation.  The extended 
conformation exists either with a closed head conformation similar to that in the inactive 
bent conformation or an open head conformation that allows for ligand ligation 91,93,94,116.  
The Integrin α5β1 primarily recognizes fibronectin as its ligand while αvβ3 binds to 
numerous extracellular matrix and secreted proteins including vitronectin and fibronectin 
117.  If fibronectin ligation results in an increased population of Integrins in the open and 
extended conformation and Tie2 is only capable of binding to the Integrin in the 
extended form, then fibronectin would result in a quantifiable increase in complex. 
A second explanation is that full length fibronectin binds directly to Tie2 and brings 
the two receptors together through a secondary contact.  The direct binding theory 
appears likely as the full length human protein, but not the fibronectin 9-10 construct, 
results in increased complex in vitro.  Fibronectin 9-10 protein contains the 9th and 10th 
fibronectin domains of full fibronectin protein, which encompasses the canonical RDG 
binding site for Integrins as well as a small secondary Integrin association site adjacent 
to the RGD 118.  If fibronectin binding to the Integrin could result in extension of the 
protein, the 9-10 construct should be capable of eliciting this effect in a similar manner 
140
	  
	  
	  	  
to the full length protein.  However, the fibronectin 9-10 construct does not increase 
complex formation and therefore implicates regions outside of these domains in 
modulating Tie2 recognition.  Moreover, Tie1 does not involve fibronectin in its 
interaction with the Integrins.  If Tie2 and Tie1 both bind to similar interfaces, as seen in 
the in vitro competition assay, extension of the Integrin molecule would presumably be 
sufficient to increase Tie1/Integrin complexation as well.  However, fibronectin does not 
affect Tie1/ Integrin association and therefore supports the theory that there is a distinct 
site within Tie2 that ligates to fibronectin.  Presumably, this site is not conserved 
between Tie1 and Tie2.  Additional experiments to assess direct binding between 
fibronectin and Tie2 will be required to validate our hypothesis and illuminate the 
differences between Tie1 and Tie2 interactions with the Integrins.   
In fact, the capacity for Tie1 to form a similar stable association with the Integrin 
molecules was an unexpected discovery in our attempt to characterize Tie2 interactions.  
Tie1 and Tie2 interactions with the Integrins occur through similar interfaces within the 
homologous extracellular Ig and EGF domains as demonstrated through pure protein 
competition assays.  Despite using similar regions within the protein, the interactions 
between Tie1/Tie2 and the Integrin molecules do not appear to be regulated by 
fibronectin in similar manners as discussed above.  These observations indicate that the 
two complexes (Tie1/Integrin versus Tie2/Integrin) likely occur under distinct 
physiological circumstances, particularly when acknowledging that Tie1/Tie2/Integrins 
are not capable of forming a triple complex as seen in our pure protein competition 
assay.  
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A Tie1/Integrin complex may provide an interesting explanation for the unexplained 
phenotypes of Tie1 knockout mice.  Specifically, knockout of the Tie1 gene results in 
increased hemorrhage and edema 18.  The role of Tie1 in endothelial cell stability has 
not been well understood but is mimicked in upregulation of Tie1 at sites of non-laminar 
flow, especially at branchpoints within the vasculature 119.  Interestingly, and similarly to 
Tie1, it has been reported that αVβ3 is upregulated under disturbed flow conditions.  
Therefore, the Tie1/Integrin complex may play a structural role in endothelial cell 
integrity at the cell–basement membrane interface that exists between endothelial cells 
and surrounding smooth muscle support cells. Surprisingly, α5β1 was regulated in a 
different manner from αVβ3.  α5β1 protein levels were reduced in laminar flow and 
unchanged in disturbed flow, perhaps an interesting distinction between the roles of the 
two endothelial Integrins.  Further studies will be required to establish the physiological 
role of Tie1 and Integrins in endothelial integrity, as well as to differentiate functions 
between Integrin molecules. 
Finally, we were surprised to determine that Ang1 binding did not seem to stabilize 
or recruit Tie2 to the Integrin complex; though it did not interfere with Tie2 binding.  
Therefore, the Angiopoietins are not required for the interaction to occur.  Yet, with 
regard to the additional reactive αV band observed in endogenous immunoprecipitations, 
Ang-1 may have an alternate effect on αV processing and potentially downstream 
signaling responses.  Interestingly, we only observed binding of the Ang-1 fibrinogen 
domain to the Integrin, and not Ang-2, though both Angiopoietins have previously been 
implicated as Integrin binding partners.  Based on our use of the monomeric fibrinogen 
domain constructs and recently published data, it appears unexpectedly that Ang-2 is 
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capable of interacting through its N–terminal coil or super clustering domains with 
Integrins and that Ang-1 can bind using the fibrinogen domain (FD) as seen in this work.  
Additionally, fibronectin does not interfere with Ang-1 binding, which indicates several 
important points.  First, the Ang-1-FD does not bind to the Integrin interface utilized in 
fibronectin RGD ligation, and instead, a novel interface must be employed.  Furthermore, 
Ang-1 and fibronectin may be able to simultaneously influence the Integrin/Tie2 
complex through distinct binding sites to modulate endothelial physiology.  This final 
point will be discussed in greater detail in Chapter 4. 
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3.9 Materials and Methods 
Protein purification 
Integrin expression constructs were reproduced based on the work of Mehta et al 
and Xiong et al 91,120. hβ1 (residues 1-728) (TrueORF gold cDNA construct RC203818 
(Origene Technologies, inc.)) and hβ3 (residues 1-718) (TrueORF gold cDNA construct 
RC201151 (Origene Technologies, inc.)) were amplified and integrated into a 
pCDNA3.1(+)-Fc neo containing backbone by overlap PCR introducing a thrombin 
cleavage site at the C-terminus of the protein and before an IgG fragment.   hα5 
(residues 1-995) and hαV (residues 1-987) were similarly cloned into a pCDNA3.1(+)-Fc 
hygromycin backbone.  Single cell cloned stable lines for the Fc-tagged Α integrin 
constructs were created in HEK293 cells using 150mg/mL Hygromycin B (Invitrogen) for 
selection.  The appropriate Β-Fc construct was then transfected into these stable cells 
using Lipofectamine 2000 and selected for using 0.5mg/mL G418 sulfate (Gemini Bio-
Products).  The Angiopoietin receptor binding domains and Tie1 (1-4) (residues 1-445) 
and Tie2 (1-4) (residues 1-452) were purified as previously described (53).  Tie2 Full 
ectodomain (1-729) was similarly cloned with a TEV protease site replacing the 
Thrombin cleavage site.   Briefly, stable cell lines were grown in roller-bottle culture and 
secreted protein was purified from the media using a packed Protein-A sepharose 
column on an Akta Purifier FPLC system (GE).  Pure IgG tagged protein was then 
cleaved overnight at room temperature using 2U/mg Thrombin (Novagen) or a 1:300 
ratio of purified TEV to target protein and separated from the Fc tag using a HiTrap 
Protein-A HP column (GE Healthcare).  Any minor contaminates were eliminated by 
using a Superdex 200 10/300 size exclusion column (GE Healthcare).  
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A fibronectin 9-10 construct obtained from Dr. Timothy Springer was transformed 
into electrocompetent BL21 (DE3) cells and used to inoculate 2 liters of auto-induction 
media.  Cells were grown for 24-48 hours at 30°C and harvested at 8k rpm for 10 
minutes in an SLA-3000 Sorvall rotor.  After resuspension in 50mM Tris pH8, 300mM 
NaCl, and 10% glycerol, the cells were homogenized at 12K PSI and 17-20K PSI for the 
first and second passages, respectively.  Lysates were clarified in a TI-45 
ultracentrifuge rotor for 1 hour at 30,000*g.  Approximately 100mLs of supernatant was 
loaded onto a CoCl2 column at 1mL/min using the P-950 pump on an Akta Purifier 
FPLC column.  20mM Tris pH8, 300mM NaCl, 10% glycerol buffer was used to wash 
the His column until the absorbance decreased to zero.  A 100mL gradient into buffer 
containing 400mM Imidizole was used to elute the His tagged fibronectin protein.  
Fractions containing greater than 99% pure protein were frozen at -80°C in 10%glycerol. 
 
Co-immunoprecipitation 
6-well dishes (Greiner) were treated overnight with either PBS (Invitrogen) or 
5mg/mL fibronectin (R&D systems) diluted in PBS as indicated.  For 
immunoprecipitations of endogenous protein, EA.hy926 cells were grown on treated 
dishes until confluent, starved in serum free media for 4 hours and treated with vehicle, 
Ang-1 or Ang-2 (R&D) at 500ng/mL for 30 minutes at 37 degrees.  Cells were rinsed 
with cold PBS and scraped from the plates in 1% NP-40 lysis buffer (20mM Hepes pH 
7.4, 150mM NaCl, 1mM EDTA, and 1% NP-40 supplemented with PhosStop and 
Complete (Roche)).  Lysates were incubated on ice for 10 minutes and spun at 15k rpm 
for 5 minutes.  Clarified lysate (0.5mg) was incubated with 25mL of Protein-A beads in 
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20mM Hepes pH 7.4, 150mM NaCl, 0.1% TritonX-100 buffer (HBST) for 1 hour alone.  
The supernatant was transferred to fresh beads and incubated with 2mg of Tie2 C20 
antibody (Cell Signaling) or control overnight at 4 degrees while rotating. Beads were 
washed twice with HBST and once with HBS before addition of 1x SDS dyes and 
resolution on a 10% SDS polyacrylamide gel.  Protein was transferred to nitrocellulose 
and immunoblotted using an anti-αV antibody (Cell Signaling). 
HEK293 transfected cell lysates were immunoprecipitated in a similar manner with 
1mg of lysate, 2mg DDK antibody (Syd Labs) or IgG control, and 25mL of Protein-A 
beads overnight.  Anti-GFP (Covance), anti-HA (12CΑ5), anti-myc (9E10) and anti-DDK 
antibodies were used for immunoblotting. 
Pure protein immunoprecipitations were incubated overnight with the indicated 
protein at 5ug/mL unless otherwise indicated in 1mL of HBST buffer and 25mL of beads.  
Beads were washed as previously described and protein was separated via 10% SDS-
PAGE run at a constant 200V.  Protein was transferred to polyvinylidene fluoride 
(PVDF) at 25V, blocked for one hour in 5% (w/v) evaporated milk in TBST and 
immunoblotted overnight with antibodies against Tie2 (AB33) (Cell Signaling), β1 (Cell 
Signaling), or β3 (Cell Signaling).   
 
Molecular imaging 
Live cell FRET assays were based on earlier work40.  Images were taken 24-48 
hours post transfection of HEK293 cells using a Zeiss Observer Z.1 incubated wide-field 
microscope with a 63x glycerin Plan Neofluar DIC optic with a 1.3 NA for sensitized 
emission data. For fluorescence lifetime measurements, a Zeiss 510 Meta with a mode 
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locked 80MHz Ti:Sapphire laser and Becker&Hickl TCSPC fluorescence lifetime 
instrument was used.  The CFP variant, mTurquoise, from J Goedhart with a higher 
intensity and longer single component lifetime was used as a donor fluorophore in our 
sensitized emission and FLIM FRET based proximity experiments 114.  mTurquoise was 
excited by LED (Colibri) at 430nm through a filter cube containing a dichroic 
beamsplitter for eCFP and eYFP (Chroma 89002bs) and either an emission filter 
specific for CFP control measurements (ET470/24m) or YFP (ET535/30m) for FRET 
measurements.  YFP variants were excited at 505nm by LED and imaged through the 
YFP beamsplitter and emission filter described above for direct excitation controls.  All 
sensitized emission measurements were obtained using the same exposure time for all 
images within an experiment, generally between 500 - 800ms.  Sensitized emission 
data was analyzed using the PFRET ImageJ plugin in addition to the contrast EP plugin 
for final FRET image acquisition 121.  Pfret analysiswas performed as described in the 
Pfret manual with the addition of the contrast EP image plug in set to consistent values 
across all images.  These values were set based on the background value used for 
initial ROI selection.  Statistical analysis and graphing were performed in JMP Pro 11.  
For fluorescence lifetime measurements, a Zeiss 510 Meta with a mode locked 80MHz 
Ti:Sapphire laser and Becker&Hickl TCSPC fluorescence lifetime instrument was used.  
FLIM-FRET measurements were obtained using the Becker and Hickl SPC-130 
software in 256*256 FiFo mode with 10% laser power at 810nm.  Decay matrix 
calculation and analysis were performed in SPC-Image.   
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Chapter 4 
Physiological Changes in Response to Tie integrin crosstalk 
 
4.1 Endothelial Integrins αV and α5 are necessary for proper vessel formation 
In order to monitor internal signaling in response to crosstalk between Integrins 
and Tie receptors, we manipulated cell lines to reduce Integrin protein levels.  
Knockdown of both αV and α5 protein was accomplished via lentiviral mediated shRNA 
delivery in two endothelial cell lines, EA.hy926 cells and Telomerase Immortalized 
Endothelial (TIME) cells.  EA.hy926 cells were immortalized by fusing primary human 
umbilical vein cells with the A549 lung carcinoma cell line using polyethylene glycol.  On 
the other hand, TIME cells were transformed by hTERT introduction into neonatal 
human foreskin microvascular endothelial cells.  EA.hy926 cells maintain endothelial 
characteristics after fusion; however, TIME cells were utilized exclusively once available 
due to their pure endothelial lineage.   Interestingly, when Integrin α subunit protein 
levels were specifically targeted, the relevant β protein levels also appeared to be 
affected.  β3 levels were drastically reduced in αV knockdowns in both cell types.  
However, β1 levels were differentially affected in the two endothelial cell types.  
EA.hy926 cells had almost complete silencing of β1 yet only ~50% reduction of the 
targeted α5.  TIME cells on the other hand did not significantly alter β1 protein levels in 
response to shα5, but they did show potential cleavage of the protein when α5 was 
absent.  As can be seen in Figure 4.1, both cell types demonstrated significant protein 
reduction in response to lentiviral mediated shRNA delivery.   
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Figure 4.1 shRNA knockdown lines established in both EA.hy926 endothelial 
cells and Telomerase Immortalized Endothelial (TIME) cells. 
(A) 50% knockdown of the integrin α5 subunit was achieved using a pGipz shRNAmir 
construct for lentiviral packaging. Interestingly, β1 integrin protein levels appeared to 
be affected by the reduction of α5 mRNA levels demonstrating the dependence of β1 
protein production on α5 stability.  (B) α5 and αV protein reduction was more efficiently 
achieved in TIME cells.  β3 protein levels depended on αV stability.  However, β1 in 
TIME cells appeared to be processed differently instead of the total protein level 
being reduced. 
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The loss of both integrins α5 and αV affected endothelial specific function as 
demonstrated by a vascular tube formation assay.  Though the cell types created tubes 
on differing time scales, both α5 (Figure 4.2) and αV (Figure 4.3) significantly reduced 
tube formation when compared to shControl cell lines.  The Angiopoietin ligands, 
particularly Ang-1, were able to increase tube formation in the knockdown cell lines 
presumably through their primary receptor Tie2 though this stimulation did not 
sufficiently compensate for the loss of the Integrin protein.  Overall, the Integrins αV and 
α5 are essential for proper endothelial cell regulation and function in these lines. 
 
4.2 AKT is not primarily regulated by Integrin/Tie2 crosstalk 
Initial experiments to evaluate downstream signaling effects of Integrin activation 
were conducted in EA.hy926 endothelial cells pre-plated on fibronectin and analyzed 
after cell growth and division for 24 hours.  Reasonably, we were unable to see a 
response as determined by FAK phosphorylation and therefore were required to modify 
our protocol in TIME cells.  To evaluate Integrin activation by stimulation with fibronectin, 
TIME cells had to be trypsinized and incubated in serum free media in suspension for 
one hour before plating on either PBS treated control plates or fibronectin treated plates.  
As shown in Figure 4.4, lysis at very brief time points resulted in observable changes in 
FAK phosphorylation at residue 397 in response to fibronectin.  Therefore, the coating 
of our dishes was in fact having a cellular effect, which we were previously unable to 
establish.  Next, we looked to evaluate Akt signaling, the primary downstream signaling 
partner of Tie2, in response to fibronectin in this assay. Under these conditions, and 
despite a significant increase in Akt phosphorylation upon plating, fibronectin did not 
151
	  
	  
	  	  
  
Figure 4.2 Reduced α5 protein levels in EA.hy926 cells leads to reduced 
angiogenesis. 
α5β1 integrin is essential for proper angiogenesis in EA.hy926 cells.  Though Ang-1 
can partially rescue this phenotype, it is likely working through its primary receptor 
Tie2 to improve endothelial function. 
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Figure 4.3 Reduced αV protein levels in TIME cells leads to reduced 
angiogenesis. 
Similarly, αVβ3 integrin is essential for proper angiogenesis in TIME cells.  Ang-1 
appears to slightly increase tube formation in the shαV cells though as previously 
stated, this action is likely due to increased Tie2 receptor activation. 
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appear to affect Akt activation in our cells.  Therefore, we decided to examine other 
signaling molecules as potential targets of receptor collaboration. 
 
4.3 Cross talk between the Tie receptors and Integrin molecules modulates 
downstream signaling cascades to control proliferation and migration 
 To thoroughly understand the intracellular effects of Tie/integrin association, 
Telomerase Immortalized Endothelial (TIME) cells were used to examine downstream 
signaling effects of the Angiopoietins and fibronectin in combination.  As stated 
previously, suspended TIME cells were incubated at 37°C with shaking for one hour in 
serum and growth factor free EBM-2 media and plated with or without Angiopoietin 
ligand on either PBS treated plates or plates that had been coated overnight with 
10µg/mL fibronectin.  Phosphorylation effects were observed in lysates harvested 15 
minutes post plating.  Ang-1, Ang-2 and fibronectin alone do not significantly effect 
MAPK phosphorylation at the 15 minute time point shown in our assay (Figure 4.5 and 
4.6).  Fibronectin did show an increase in phospho-MAPK on its own at later time points, 
specifically 30 minutes.  Even though Ang-1 did not affect MAPK alone at these time 
points, it has been shown previously to initiate MAPK phosphorylation on its own in 
other systems (Figure 4.5).  Interestingly, at 15 minutes, the combination of Ang-1 and 
fibronectin coating showed a significant increase in phospho-MAPK by western blot 
analysis. In contrast, Ang-2, and the combination of Ang-2 and fibronectin, showed no 
significant effects though, there was a trend toward decreased MAPK phosphorylation 
when stimulated with Ang2 alone.  
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Figure 4.4 Activated AKT and FAK signaling in TIME cells. 
FAK signaling was undetectable in cells plated on fibronectin and stimulated with 
Angiopoietins at 24 hours.  To analyze signaling at early time points, TIME cells were 
trypsinized, washed, and incubated in suspension in serum free media for one hour 
before plating on fibronectin or PBS treated wells with Angiopoietins.  Cells were 
lysed after the indicated time period and analyzed by western blot using antibodies 
from Cell Signaling.  Though there did not appear to be a significant change in 
phospho-AKT signaling with fibronectin at these time points, FAK signaling was 
responsive to fibronectin particularly at earlier time points. 
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Figure 4.5 ERK1/2 MAPK is modulated by the combination of Tie2 and integrin 
ligands. 
A time course was completed using the method described in Figure 4.4 to analyze 
MAPK activation of p42/44.  Interestingly, MAPK phosphorylation is increased at the 
15-minute time point in response to the combination of fibronectin and Ang-1 but not 
with stimulation by either ligand alone.  After 30 minutes, fibronectin appears to 
activate the pathway without the requirement of Ang-1.  At one hour, signaling 
appears to be similar despite stimulation.   
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 When monitoring FAK phosphorylation 15 minutes following cell plating, the 
Angiopoietins demonstrated little to no effect on this signaling cascade.  Alternatively, 
as expected cells plated on fibronectin demonstrated a consistent and significant 
increase in Y397 phosphorylation of FAK.  As projected, when α5 integrin protein was 
silenced by lentiviral mediated shRNA delivery (Figure 4.6), cellular FAK 
phosphorylation levels were similarly reduced.  Interestingly, under these conditions, we 
also observed a drop in Ang-1/fibronectin induced MAPK phosphorylation levels 
indicating that the Integrin α5 is essential for the proliferation and migration signal 
activation in response to the combination of Ang-1 and fibronectin. 
 
4.4 Concerted prolonged signaling in response to fibronectin and Ang-1 
decreases pro-survival signaling in endothelial cells 
Despite observing similar Akt activation levels in response to fibronectin through 
2 hours of stimulation, we wanted to see if the primary target of Tie2 activation was 
affected after prolonged exposure to fibronectin.  Therefore, confluent shControl cells 
and stable α5 knockdown cells were stimulated with PBS control, 500 ng/mL Ang-1 or 
500 ng/mL Ang-2.  As expected Ang-1, but not Ang-2, stimulated phosphorylation of Akt 
at threonine 308 as established through the PI3K pathway. Cells with decreased levels 
of α5 protein did not significantly affect Akt phosphorylation in response to Ang1 (Figure 
4.7).  There was, however, a minor increase in phosphorylation at threonine 308 after 
Ang-1 stimulation when compared to shControl cells, suggesting that Integrin protein 
might inhibit Ang-1 signal activation of Akt through Tie2.   No change in phosphorylation 
levels was observed for either vehicle treated or Ang-2 treated cells between the control 
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Figure 4.6 ERK1/2 is coordinately regulated by the Tie2/Integrin complex in 
response to the combination of Ang1 and fibronectin stimulations.  Serum 
starved Telomerase immortalized endothelial cells (TIMEs) were plated on control 
treated or fibronectin treated dishes with either vehicle stimulation, 500ng/mL Ang1, 
or 500ng/mL Ang2 for 15 minutes before lysis with NP-40 lysis buffer.  Cell lysates 
were resolved by SDS-PAGE and blotted for p-ERK1/2 / ERK (A) and p-FAK/ FAK 
(B).  (C and D)  Integrin α5 protein levels were decreased using shRNA in TIME cells.  
(C) Ang1 stimulated shControl cells or shα5 TIME cells were plated on either PBS 
treated or 5ug/mL fibronectin treated plates were lysed and probed for p-ERK1/2 / 
ERK1/2 or (D) p-FAK / FAK.  Graphs presented in Figure 4.6 were a compilation of 3 
independent experiments.  * indicates student t-test values of p<0.05 and error bars 
represent the standard error. 
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and shα5 cell lines.  Interestingly, when we attempted to evaluate the effect of the 
Integrin ligand fibronectin in our assay we were unable to see a response to stimulation 
even in control cells and therefore were required to modify our protocol in TIME cells.   
 Furthermore, Akt was observed in response to fibronectin plating after 24 hours 
with and without Angiopoietins.  Consistent with the observed increase in α5 knockdown 
cells, Akt phosphorylation levels were decreased in response to Integrin activation by 
fibronectin (Figure 4.8).  Therefore, it appears that MAPK is activated early in ligation to 
fibronectin in the presence of Ang-1.  Alternatively, Akt signaling is reduced in the 
prolonged presence of fibronectin with Ang-1.  Finally, FAK was not affected by 
crosstalk between Tie2 and α5β1.   
 
4.5 Conclusions 
 Through analysis of multiple established downstream signalling targets of the 
Integrins and Tie2 individually, we established a physiological response to cross-talk 
between these two distinct receptor families.  Though the prominent signaling partners 
Akt and Focal Adhesion Kinase (FAK) were not synergistically affected in response to 
stimulation by ligand combinations at early time points, MAPK phosphorylation was 
significantly increased in the presence of both fibronectin and Ang-1.  Interestingly, at 
15 minutes, neither fibronectin nor Ang-1 activated MAPK alone. Additionally, 
phosphorylated MAPK levels were reduced in the shα5 cell line compared to control, 
demonstrating a dependence on the Integrin molecules for these signalling events to 
occur. Therefore, it appears that sensitized early activation of proliferation and migratory 
signaling from MAPK requires the concerted efforts of Tie2 and α5β1. 
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Figure 4.7 AKT activation shows a slight increase when Integrin protein levels 
are reduced.   
As expected, Ang-1 increases AKT phosphorylation at residue threonine 308.  As our 
initial candidate for targeting by crosstalk between the integrins and Tie2, we looked 
at the effect of reducing protein levels of α5 on AKT activation by Tie2.  There did not 
appear to be a significant change between Ang-1 stimulated levels though there may 
be a slight increase in phosphorylation. 
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Figure 4.8 Akt activation seen in response to Ang-1 24 hours after plating is 
reduced with the addition of fibronectin. 
TIME cells were plated on fibronectin for 24 hours, serum starved for 4 hours and 
stimulated with PBS vehicle, Ang-1, Ang-2, or rhVEGFA165 for 30 minutes before 
lysis.  Western blot analysis of Akt phosphorylation at threonine 308, serine 473 and 
total Akt revealed similar regulation at both sites. Activation of Akt was not seen with 
fibronectin alone or Ang-2.  However, as expected Ang-1 significantly increased 
activation at both sites.  Interestingly, cells plated on fibronectin for 24 hours showed 
reduced survival signaling after Ang-1 stimulation compared to cells plated on PBS 
treated plates.  Alternatively, rhVEGF165 showed only slight activation of Akt at 
threonine 308 and was not regulated by fibronectin.   
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 Consistently, despite finding that Akt was not significantly affected at early time 
points when exposed to ECM, at 24 hours it appears that Ang-1 and fibronectin 
combined stimulation decreases pro-survival signalling compared to Ang-1 alone.  
Similarly, cells with reduced Integrin levels showed increased Akt phosphorylation 
compared to shcontrol cells.  Therefore, it seems that early contact with fibronectin in 
the presence of Ang-1 results in migratory or proliferative signalling.  However, the 
effect of fibronectin/Ang-1 stimulation on pro-survival signalling requires prolonged 
exposure to the ECM.  
 Based on several studies in the literature, it is known that Tie2 is spatially 
regulated in endothelial cells 36,37.  Specifically in confluent cells, Tie2 sitting at cell-cell 
contacts is clustered by Angiopoietin-1 and primarily results in activation of Akt.  On the 
other hand, Tie2 activated in sparse cells by Ang-1 signals through the pro-migratory 
pathway, MAPK.   Our data have furthered the understanding that direct complex 
formation with Integrin molecules at sites of ECM contact mediates MAPK activation.  
Conversely, Tie2 clusters occurring in the absence of Integrin protein at cell-cell 
contacts mediate Akt activation and that engagement of Integrin contacts disrupts this 
prosurvival signaling.  Our model is presented and further discussed in Chapter 6.   
 Interestingly, fibronectin and α5β1 act at sites of pericyte recruitment to 
upregulate proteins of the basement membrane matrix and stabilize the growing stalk.  
Without fibronectin and α5β1 at sites of initial stalk stabilization, the endothelial channels 
fail to properly form and the supporting basement membrane is not appropriately 
deposited 75.  Intriguingly, Ang-1 is secreted from pericytes, providing a physiological 
time point for α5β1 / Tie2 / Ang1 interactions to play an important role in angiogenesis.  
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Additionally, Ang-1 knockout mice exhibit sparse ECM that lacks fibers.  Furthermore, 
Ang-1 knockout mice have dilated vessels, demonstrating altered tube formation in 
these animals 53. Potentially, these phenotypes demonstrate that Ang-1 plays a role in 
α5β1 induced fibrillar adhesions and proper fibril formation.  Furthermore, Tie2 
associates with Integrin complexes to help sense changes in the extracellular 
environment.  Perhaps Ang1/ Tie2/ α5β1 complexes signal endothelial cells to begin 
proliferation for proper lumen formation upon recruitment of pericytes. 
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4.6 Materials and Methods 
Cell culture and manipulation 
HEK293t and EA.hy926 cells (ATCC) were cultured in Dulbecco’s Modified Eagles 
Medium (Invitrogen) with 10% Fetal Bovine Serum (Gemini Bio-Products), 100 U/mL 
Penicillin and 100 ug/mL Streptomycin (Gibco Life Technologies).  Stimulations were 
performed when cells reached 80-90% confluence using Lipofectamine 2000 
(Invitrogen) according to manufacturers’ instructions either in 6-well dishes for 
immunoprecipitations (Greiner) or 35mm glass bottom culture dishes for imaging 
analysis (MatTek).  Equimolar concentrations of plasmid vectors were used for 
transfections when necessary.  Telomerase-immortalized microvascular endothelial 
(TIME) cells (ATCC) were grown in Endothelial Basal Media-2 (EBM-2) supplemented 
with the Endothelial Growth Media-2 (EGM-2) Microvascular (MV) SingleQuot kits 
(Lonza). 
 
Lentiviral-mediated protein reduction 
HEK293t cells were transfected with the pGipz control vector or the pGipz shRNAmir 
containing plasmids targeting α5 (clone number 133433) or αV (clone number 133468) 
using the Arrest-In lipid transfection reagent (ThermoScientific) in serum and antibiotic 
free media.  After three hours of incubation, DMEM containing 10% FBS, 100 U/mL 
Penicillin and 100 ug/mL Streptomycin was added.  After an additional 48 hours, the 
virus was harvested from the media following clarification by centrifugation at 3000rpm 
for 20 minutes.  The viral supernatant was added directly to EA.hy926 or TIME cells at 
~80% confluency and incubated for 48 hours.  Transduced cells were selected using 1 
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µg/mL of puromycin (Invitrogen) until the cells were 100% GFP positive.  Protein levels 
were checked by western blot using antibodies to α5, αV, β1, β3 (Cell Signaling) and actin 
proteins (Sigma-Aldrich). 
 
Tube Formation Assay 
 ShControl, α5, or αV knockdown cell lines described above in either EA.hy926 or 
TIME endothelial cells were plated on Matrigel in Ibidi u-slide angiogenesis plates. 
10,000 endothelial cells suspended in serum free media were plated per well on 10uL of 
matrigel and incubated with PBS vehicle, 500ng/mL Ang-1, or 500ng/mL Ang-2.  Wells 
were imaged every hour by DIC on a widefield Zeiss Observer Z.1 microscope with a 
63x glycerin objective with 1.3 NA.   
 
Tie2 Activation Assays 
6-well plates were treated with either PBS or 10 µg/mL fibronectin overnight at 4 
degrees.  TIME cells were trypsinized (Invitrogen), quenched with full media, and spun 
at 1000rpm for 5 minutes.  Pelleted cells were resuspended in serum free media and 
incubated at 37 degrees with shaking for 1 hour.  Serum free media was added to either 
PBS or fibronectin treated dishes with vehicle, Ang1 at 500 ng/mL or Ang2 at 500 ng/mL.  
Suspended cells were distributed equally in the wells and allowed to incubate at 37 
degrees for 15 minutes.  Cells were washed in cold PBS and lysed as described 
previously.  50mg of cell lysate was resolved via SDS-PAGE and immunoblotted for 
total Akt, MAPK, and FAK or specific phosphorylated residues (threonine 308 of Akt, 
threonine 202 and tyrosine 204 of MAPK, or tyrosine 397 of FAK (Cell Signaling)).  
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Densitometry was performed using gel analyser software (Fiji) and statistically analysed 
with JMP Pro 11. 
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Chapter 5 
Structure analysis of an Ang-1 α5β1 complex 
 
 
Several reports in the literature have implicated Angiopoietin ligands as binding 
partners of the integrin adhesion molecules primarily through plate adhesion assays and 
antibody binding studies that interrupted the predicted interaction.  Interestingly, these 
interactions have been observed not only in endothelial cells but also in cardiomyocytes, 
breast cancer cell lines and neurons 105,107,122,123. Broadening the number of cell types 
Angiopoietins can influence significantly expands their potential influence within the 
body.  Though two of these reports associate Ang-1 with the Integrins α5β1 and/or αVβ3, 
the third paper describes an interaction with Ang-2 and the Integrins.  None of the 
reports assessed both Angiopoietins simultaneously. 
5.1 Purification of an Ang-1/α5β1 complex by gel filtration 
As described in Chapter 3, we discovered an interaction between the Integrin 
α5β1 and Ang-1, but not the Tie2 antagonist Ang-2.  To further evaluate Ang-1’s ability to 
bind α5β1, tag free purified components were complexed on ice for 1h, incubated with 
the crosslinking reagent 3,3'-dithiobis(sulfosuccinimidyl propionate) (DTSSP) for 2 hours 
and chromatographed on a SD200 size exclusion column to monitor complex formation.  
Ang-1 fibrinogen domain binding to α5β1 induced a shift in the elution profile of Ang-1 
consistent with formation of a 1:1 Ang-1/α5β1 complex (Figure 5.2).  The complex will 
also form in the absence of DTSSP as demonstrated by precipitation with ProteinA 
beads; however, this formation occurs in limited amounts suggesting an interaction with 
low affinity.  The eluted protein complex and each of the individual proteins were 
investigated by Small Angle X-ray Scattering.   
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5.1 SDS-PAGE evaluation of proteins subjected to complexation and analysis 
by SAXS.   
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Figure 5.2 Direct association between Ang-1-FD and α5β1 by size-exclusion 
chromatography.  
Indicated fractions were run on a 10% SDS-PAGE gel with low molecular weight 
markers. Top panel: Purified α5β1 ectodomain was chromatographed on a Superdex 
200 column and elutes as a single peak at ~12mL. Middle panel: Purified Ang-1 
elutes from a Superdex 200 as a single peak at ~17mL. Bottom panel: α5β1 purified 
protein was cross-linked to a 1.5 molar excess of Ang-1 using DTSSP and separated 
on a Superdex 200 column.  Under these conditions, Ang-1 now elutes in a complex 
with α5β1 at ~11.5mL.  
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5.2 SAXS analysis of individual Ang-1 and α5β1 protein solutions 
As shown in Figure 5.3, SAXS provided distinct scattering profiles for the 
complex and the two individual proteins in solution.  Interestingly, when we examined 
the Ang-1 fibrinogen domain alone compared to the known monomeric crystal structure, 
the fit was fairly poor at a chi of 3.51.  Similar to the finding in Chapter 2 that Ang-2 
could form transient dimers in solution through the fibrinogen domains, it appears that 
Ang-1 is capable of weak homo-dimeric interactions in solution as well.   Though the 
dimer fit poorly to the solution (chi=4.42), a mixture of approximately 55% monomer and 
45% dimer fit to the experimental data at 0.98 chi (Figure 5.4).   
The crystal structure of the full αVβ3 extracellular domain revealed an unexpected 
bent conformation adopted by the protein within the crystal lattice 91.  The crystal 
structure and subsequent solution data revealed that Integrin molecules undergo 
substantial conformational changes between the leg domains and the head groups of 
the α and β subunits that regulate activation of these adhesion molecules 92.  The 
crystal structure of α5β1 has also been solved though the extracellular domains of the α 
and β subunits were truncated to contain only the head domain of the protein 93.  
Therefore, the full extracellular domain of α5β1 was modeled for SAXS analysis based 
on the known structure of the highly homologous αVβ3. 
 When fitting the bent conformation of the modeled structure to the SAXS 
experimental data of α5β1, we see that the crystal structure-based conformation is 
significantly smaller and has a globular fold compared to the more extended nature of 
the protein in solution (Figure 5.5).  To attempt to accurately model this protein, our 
collaborators Dr. Michael Hammel and Caroline Weiss added carbohydrate chains to 
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Figure 5.3  SAXS Scattering Profiles for the Ang-1/α5β1 complex 
Intensity versus q plot for Ang-1 alone (red), α5β1 alone (yellow) and α5β1 in complex 
with Ang-1 (grey) all at high concentrations.   
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Figure 5.4  Ang-1 exists in solution as a transient mixture of monomer and 
dimer.   
FOXS analysis of Ang-1 revealed that the monomeric fibrinogen domain crystal 
structure did not represent Ang-1 in solution when compared to the experimental 
scattering profile with a chi of 3.51.  When compared as a dimer, the chi value 
increased to 4.42; however, using minimal ensemble analysis within FOXS to 
represent the solution as a mixture of monomer and dimer, the profile fit with a chi of 
0.98 for 56% monomer and 44% dimer.   
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Figure 5.5  Comparison of the α5β1 experimental data to the crystal structure 
and generated models. 
The P(r) function for α5β1 alone (black) depicted a much larger molecule in solution 
than that of the crystal structure (PDB:).  The crystal structure (pink) was solved in a 
severely bent, presumably inactive conformation that likely does not exist in nature 
when incorporated into the plasma membrane.  The model generated with the help of 
Michael Hammel and Caroline Weiss to describe α5β1 in solution (shown in Figure 
5.7 in blue) is a better representation of the solution scattering as conveyed by the 
P(r) curve.  Interestingly, we can identify the head group globular structure as the first 
peak in the small distance region and the extended legs as the subsequent peaks.   
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Figure 5.6  α5β1 exists in multiple open conformations in solution. 
Based on FOXS analysis of α5β1, the crystal structure does not appear to fit the 
experimental solution in agreement with evaluation using the P(r) function.  
Interestingly, the best fit to the experimental data was a mixture of two open 
conformations of α5β1 with variation at the angle between the head and leg groups.  
This suggests that there is flexibility at the “knee” joint and likely interminable 
conformers of this open state in solution. 
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the known and predicted glycosylation sites of the protein since these molecules are 
acknowledged to contribute to scatter profiles.  Additionally, they created multiple open 
conformations of α5β1 alone with varying angles adopted at the ‘knees’ of the protein.  
Based on FOXS fitting of the theoretical scattering profiles created for the models 
compared to the experimental data, a mixture of open conformers fit to the data, while 
the bent conformation seen in the crystal structure does not appear to appreciably 
contribute (Figure 5.6). 
5.3 Complex Evaluation by Small Angle X-ray Scattering 
As expected, there was not a significant change in overall size with the addition 
of Ang-1 to α5β1, considering the small size of Ang-1 in comparison to the over 200kDa 
complex of the extracellular domains of α5β1.  The Rg reflects a small increase in 
general size from 51.8 for α5β1 alone to 53.1 for the complex.  The primary change seen 
in the P(r) function (Figure 5.7) exists within the large globular domain of the protein as 
opposed to the extended Ig-like domains that create the thigh and calf domains of the 
protein subunits.  Confirming this observation, models of Ang-1 placed within the head 
domain of α5β1 have a significantly improved fit to the complex experimental data 
compared to either α5β1 alone or the bent conformation of α5β1 with Ang-1.  Similar to 
α5β1 alone, a mixture of two open conformers seen in Figure 5.8 fit well to the 
experimental data with 67% of the largest angle opening and 33% of a slightly closed 
conformation.    
Additionally, ab initio modeling was completed for α5β1 and α5β1 + Ang-1 using 
the ATSAS suite program GASBOR to generate 20 models for each solution.  These 
models were subsequently averaged and filtered using DAMAVER to provide the 
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Figure 5.7 Ang-1 complex formation results in slight differences in the P(r) 
function. 
The α5β1 alone experimental curve and the α5β1/Ang-1 complex P(r) functions are 
very similar particularly in the leg domain region.  This is expected since Ang-1 is 
small compared to the large α5β1 protein.  Interestingly, it appears that the primary 
difference between the two protein solutions occurs within the globular head domain. 
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Figure 5.8. α5β1 exists in the open conformation when interacting with Ang-1. 
(A) Analogous to the α5β1 alone data, the complex solution scattering did not 
correlate with the model of the crystal structure bound to Ang-1, as seen in panel A.  
Two open structures with varying angles at the knee joints fit to the experimental 
curve better than the bent conformation. (B) Minimal ensemble analysis of the 
varying models revealed that the two open conformations fit to the experimental data 
at 67% and 33%.  Interestingly, it appears that Ang-1 may have shifted the open 
conformation to the more extended model though further analysis is necessary to 
confirm this hypothesis. 
191
	  
	  
	  	  
  
192
	  
	  
	  	  
protein envelopes shown in Figure 5.9.  The α5β1 alone GASBOR model is depicted in 
solid silver and compared to the α5β1 + Ang-1 model in blue mesh.  There appears to be 
additional space adjacent to the head domain of α5β1 in the complex ab initio 
reconstruction that fits well with the addition of the Ang-1 crystal structure shown in 
yellow.  Mutational analysis of the integrin head domain and regions of Ang-1 will be 
required to narrow the specific residues necessary for the interaction to occur. 
5.4 Discussion 
Despite elution of Ang-1 as a monomer by size exclusion, our SAXS analysis of 
the Ang-1 protein solution was not represented well by the monomeric crystal structure.  
Surprisingly, the experimental data fit with a chi value of 0.98 when represented as a 
mixture of 56% monomer and 44% dimer.  Based on the elution profile of this growth 
factor, the dimerization interaction is likely low affinity and disrupted by gel filtration.  
Similarly, in Chapter 2, we identified a low affinity interface within the fibrinogen domain 
of Ang-2 at 10mg/mL.  Therefore, a transient association between the receptor-binding 
domain of these two Angiopoietin ligands occurs, though only at high concentrations.   
Additionally, by SAXS, we revealed an extended conformation of the α5β1 protein 
at multiple open angle conformations in solution.  We did not see significant contribution 
of the bent conformation solved in crystallographic studies.  This crystal structure was 
presumed to be an artifact of crystal packing and too compact to exist in nature, 
particularly in the presence of a plasma membrane 91,124.  Therefore, we believe that 
protein flexibility between the calf domains and the thigh and head groups of the α and 
β subunit allows for an assortment of conformations to exist in solution, containing a 
wide variety of angles emanating from the knee.   
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Figure 5.9.  ab initio modeling of α5β1 and α5β1/Ang1 complex reveals potential 
binding site of Ang-1 at the α5 head domain. 
Twenty rounds of GASBOR ab initio modeling for both α5β1 and the α5β1/ Ang-1 
complex were completed and averaged using DAMAVER.  The α5β1 alone ab initio 
model is shown in silver; α5β1/Ang-1 complex is depicted as the surrounding blue 
mesh; and Ang-1 has been placed in the second and forth model to show the fit 
within the models. 
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Through complex formation and SAXS analysis, we determined the interaction 
between the Angiopoietin ligand, Ang-1, and the ectodomain of α5 to be direct and 
identified a novel binding site for the protein.  Gel filtration of the complex versus Ang-1 
protein alone demonstrated a significant shift in elution size when incubated with α5β1 
prior to separation.  As expected, the elution profiles of α5β1 did not change dramatically 
with complexation. Addition of the small globular Ang-1 fibrinogen domain did not 
significantly affect the overall size and shape of our protein enough to be observed by 
the resolving power of the SD200 10/300 column in this range   
SAXS analysis further confirmed complexation of our proteins and indicated an 
altered shape in the globular region (likely the head domains) of the protein as seen in 
P(r) function plots.  The leg domains are represented by the extended portion of the P(r) 
function and do not change with the addition of Ang-1.  Additionally, from FOXS 
analysis of the experimental scattering profiles, it appears that Ang-1 may result in 
further opening of the α5β1 knee angle, an observation that will require further validation.  
Finally, ab initio reconstruction of α5β1 versus the α5β1/Ang-1 complex revealed extra 
predicted area within the envelope of the complex adjacent to the head domains of α5β1.  
From structure placement within the envelopes, Ang-1 protein occupies the size and 
shape of the additional envelope area presumably adjacent to the WD-40 repeats of α5.  
The precise residues responsible for association will require future mutagenic 
evaluation. 
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5.5 Materials and Methods 
Protein Purification  
Proteins were purified as described in detail in Chapters 2 and 3. 
Complex Formation by Gel Filtration 
Purified integrin α5β1 and Ang-1 were complexed using a reversible cross-linking 
reagent and gel filtration chromatography.  Similar to complex formation performed in 
Chapter 2, a 2 molar excess of the small Ang-1 ligand was employed to ensure 
complete complexation of the integrin in solution.  500µg of α5β1 (5µM) was incubated 
for one hour on ice with 150µg Ang1-FD (10µM) in running buffer (1% glycerol, HBS, 
2mM Mg2+ and 2mM Mn2+).  250µM DTSSP crosslinking reagent was added to the 
incubating complex and remained on ice for two hours.  The reaction was quenched 
with 40mM Tris pH 7.4 for 20 minutes on ice before filtering the solution through a 
0.22µm filter and running the complex on an SD200 column in the running buffer 
described above.  The complex was concentrated to 1, 3 and 10 mg/mL and sent, along 
with similar concentrations of the individual proteins for SAXS analysis. 
SAXS Sample Preparation and Data Analysis 
SAXS protein samples were prepared as described in Chapter 2 and sent to 
Lawrence Berkeley National Labs with the Sibyls Beamline.  Dr. Michael Hammel and 
Caroline Weiss aided significantly in the evaluation of the Integrin / Ang-1 SAXS data 
and analysis. 
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Chapter 6 
Conclusions 
Integration of Tie/ integrin signaling in Angiogenesis 
 
Both the Angiopoietin/Tie family of growth factor receptors and the Integrin 
adhesion molecules are essential for proper blood vessel development and 
angiogenesis throughout adult life 17,19,78.  Ang-1, secreted from support smooth muscle 
cells, promotes clustering of Tie2 and activation of prosurvival signals to maintain the 
quiescent endothelium 109.  Alternatively, Ang-2 is proangiogenic, and after VEGF 
stimulation, disrupts Tie2 contacts at cell junctions to promote migration and branching 
of a new vessel 55.  
Through experiments conducted in this body of work, we propose that during 
active angiogenesis Tie2 is redistributed around the membrane and interacts with 
Integrins, specifically αVβ3, which is upregulated at sites of activation and appears to be 
a sensing Integrin.  αVβ3 recognizes a variety of both pro-angiogenic and anti-
angiogenic signals potentially resulting in its ability to decide between persistent 
migration towards angiogenic stimuli or random movement in an attempt to locate 
proangiogenic stimuli 74.  Likely, αVβ3 interacts with either a Tie RTK to help sense the 
prominent angiogenic signal, Ang-2, or interacts with the N-terminal domain of Ang-2 
itself as has been described in the literature 89.  During this searching process, αVβ3 
forms transient focal contacts that can either dissociate or mature into focal adhesions 
to continue along a gradient.  The maturing focal adhesions incorporate α5β1, which 
upon clustering in response to fibronectin will increase the strength of the cell–ECM 
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attachment.  Further maturation of the focal adhesion results when α5β1 migrates out of 
focal adhesions, where it exists in concert with αVβ3, to form α5β1 only fibrillar adhesions 
responsible for regulating basement membrane development and fibronectin fibril 
formation 81.  Interestingly, α5 and Ang-1 knockout mice have overlapping phenotypes; 
specifically, they both show fibril deficiency in the basement membrane and enlarged 
vessel diameters 51.  The overlapping phenotypes of these two distinct pathways 
suggests that Ang-1 and α5 collaborate at sites of vessel maturation to direct proper 
lumen formation and mature basement membrane deposition.  Rearrangement of the 
basement membrane occurs when the stalk behind a migrating tip cell transitions to 
lumen formation to create a functional conduit.  
Furthermore, stability of the growing stalk appears to be uniquely regulated by 
the Tie receptor axis.  Tip endothelial cells release the growth factor PDGFB to recruit 
smooth muscle support cells expressing PDGFRβ to the growing stalk.  These cells are 
the predominant producers of Ang-1 and contribute to elements of the mature basement 
membrane surrounding quiescent vessels 7.  We believe that Tie2 associated with 
Integrins at sites of new pericyte recruitment, interact with Ang-1 and promote 
proliferation to complete lumen formation of the stalk.  Once endothelial cells 
encompass the conduit, cell-cell contacts will form and Tie2 will preferentially cluster 
without Integrins at these junctions 37,125.  At this time, an exchange from Tie2 to Tie1 
interaction with Integrins could be important for delineating the end of proliferation within 
the forming stalk to the prosurvival signaling of Tie2 at junctions.  Relevantly, Tie1 
knockouts exhibit overgrowth of endothelial cells into the lumen of blood vessels 
indicating that Tie1 is required to negatively regulate excessive proliferation 42.  
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Additionally, Tie1 is known to play a role as a decoy receptor for Tie2 signal termination 
through disruption of Tie2 clusters 40.  Therefore, its ability to act as a Tie2 decoy with 
respect to the Integrin receptors seems like a logical conclusion.   
Furthermore, the concept of Tie1 interacting with Integrins in quiescent 
endothelial cells could provide an interesting explanation for additional unexplained 
phenotypes of the Tie1 knockout mice 17.  Particularly, Tie1 knockouts display increased 
edema and hemorrhage, phenotypes that are not well explained by its specific role in 
Tie2 cluster disruption.  Alternatively, Tie1 interacting with Integrins at sites of cell-
basement membrane contacts could work to bolster endothelial cell stability.  Tie1 is 
also known to be upregulated at sites of disturbed or non-laminar flow typically at 
branch points within the vasculature 119.  Furthermore, αVβ3 was demonstrated to have 
increased expression at sites of disturbed flow and could work in concert with Tie1 at 
these sites to maintain endothelial adherence to the basement membrane 126.  
Interestingly, α5β1 was not found to be upregulated at branch points and could indicate a 
distinction between these highly compensatory Integrins.  The model shown in Figure 
6.1 depicts the spatial regulation of Tie2 through its distinct physiological roles at sites 
of cell-cell contact in the quiescent endothelia versus Integrin interaction in migrating or 
proliferating cells.  Through dissemination of this work, we hope to improve 
understanding of Angiopoietin signaling and Tie2 receptor crosstalk within angiogenesis.  
200
Figure 6.1 Proposed model of Integrin/Tie2 cooperative signalling in 
endothelial cell regulation. (A) In quiescent endothelial cells, it has been shown 
that Ang1 clusters Tie2 at cell-cell contacts by several groups.  Tie2 plays a major 
role in maintaining the integrity of the blood vessel wall by providing pro-survival 
signals for example through AKT and Survivin.  While Tie2 is tethered at cell-cell 
junctions, it likely interacts with VE-Cadherin and VE-PTP to regulate adherens 
junction formation and dissociation.  Also during maintenance of quiescent vessel, 
we believe that Tie1 and the endothelial Integrins, either αVβ3 or α5β1, are secured to 
the basement membrane extracellular matrix components.  A link between Tie1 and 
the extracellular matrix in the lining of the vasculature would explain a role for Tie1 in 
vessel integrity and shear stress that has previously been described yet unexplained. 
(B) After disruption of cell-cell junctions by pro-angiogenic factors such as Ang-2 and
VEGF during the initiation of angiogenesis, homogenous Tie2 clusters are disrupted.
Tie2 is no longer tethered at cell junctions and can now interact with Integrins at sites
of provisional extracellular matrix.  Tie2 interacting with the Integrins signals through
ERK/MAPK to prolong migration and proliferation during branching and lumen
formation.
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